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Abstract 
Mature Dendritic Cells Use Endocytic Receptors to Capture and Present Antigens 
Craig Daniel Piatt 
2010 
In response to inflammatory stimuli, dendritic cells (DCs) trigger maturation, 
a terminal differentiation program required to initiate T lymphocyte responses. A 
hallmark of maturation is downregulation of endocytosis, widely assumed to 
restrict the ability of mature DCs to capture and present antigens encountered after 
the initial stimulus. W e found that mature DCs continue to internalize antigens, 
especially by receptor-mediated endocytosis and phagocytosis. These antigens 
were transported to lysosomal compartments, loaded onto MHCII, and presented 
efficiently to T cells, both in vitro and in vivo. Antigens were also presented on 
MHCI with high efficiency. While mature DCs down-regulate macropinocytosis, 
they capture antigens via endocytic receptors and, in principle, remain able to 
initiate immune responses during the course of an infection. 
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Chapter 1: Introduction 
The Immune Response 
For as long as there have been multi-cellular organisms, there have been 
simpler organisms seeking niches within their nutrient-rich hosts (Pancer and 
Cooper, 2006). While there are many examples of mutualism, invasion often 
comes at a great cost to the host (Lefevre et al., 2009). The immune system is the 
collection of mechanisms that the host employs to detect, and remove pathogenic 
threats (Murphy et al., 2007). 
The immune system can most broadly be divided into the arms of innate 
immunity and adaptive immunity (Murphy et al., 2007). The ancient innate 
immune system, present in some form among virtually all metazoan organisms, 
detects pathogens using genomically encoded receptors that recognize conserved 
microbial molecular patterns (Palm and Medzhitov, 2009; Takeda and Akira, 
2007). Pathogens recognized as foreign by these receptors trigger an inflammatory 
response and can be eliminated though any of a variety of strategies. Phagocytosis, 
opsonization, lysis through complement cascade, toxic metabolites such as reactive 
oxygen species and antibacterial peptides are just a few of the available 
mechanisms available to the host (Murphy et al., 2007). 
It was much more recently in evolutionary history (approximately 450 
million years ago) that adaptive immunity provided hosts with the ability to 
engineer custom-made receptors for each newly encountered pathogen (Cooper 
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and Alder, 2006). All vertebrates with jaws possess such adaptive immune 
systems. The somatic recombination of gene segments within antigen-receptor loci 
leads to the generation of vast populations of B cells and T cells, each expressing a 
novel receptor (Bassing et al., 2002; Schatz, 2004). These individual cells are 
capable of amplification when, by chance, their receptors find their pathogenic 
match (Bartl et al., 1994). In addition to increased specificity, adaptive immunity 
supplies jawed vertebrates with the advantage of "immunologic memory." Once a 
custom designed receptor is amplified after exposure to a foreign threat, it becomes 
a part of the host's immunologic arsenal, and is ready to quickly act in the future. 
This greatly reduces the risk of future infections by the same pathogen (Gourley et 
al., 2004). 
Dendritic Cells: Bridging Innate and Adaptive Immune Responses 
Despite the fact that medicine had been taking advantage of adaptive 
immune responses for centuries through vaccinations (Plotkin, 2005), the way in 
which the majority of adaptive immune responses are initiated was determined 
only within the past few decades. In 1973 Ralph Steinman and Zanvil Cohn 
published the first report of a unique cell type in the spleen which they termed the 
"dendritic cell" because of its numerous fine extensions (Steinman and Cohn, 
1973). Over the following years, studies revealed that they were more than 100-
fold more potent at initiating immune responses than cells such as monocytes and 
macrophages, which had previously been thought to be chiefly responsible for 
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lymphocyte activation (Steinman and Witmer, 1978). However, a better 
understanding of how these cells initiate adaptive immune responses would have 
to wait until the interconnected nature of the innate and adaptive immune systems 
was unraveled. 
When DCs were discovered, the innate immune system was considered to 
be primarily a rapid but incomplete means of controlling infection until the slower 
but more powerful adaptive immune system could be mobilized (Fearon and 
Locksley, 1996). This view was challenged by a seminal 1989 article, in which 
Charles Janeway hypothesized that the innate immune system played a vital role in 
initiating and directing adaptive immunity. His proposal was that the immune 
system distinguished pathogen derived-antigens from self-antigens by using a set of 
pattern recognition receptors (PRRs) that were capable of recognizing pathogen 
associated molecular patterns (PAMPs) Qaneway, 1989). 
Janeway's hypothesis was validated in 1997 with the discovery of a 
mammalian homologue of the insect protein known as Toll (Medzhitov and 
Janeway, 1997). In Drosophila, in addition to regulating polarity during 
embryogenesis (Hashimoto et al., 1988), Toll participates in the innate response 
against fungal pathogens (Lemaitre et al., 1996). Interestingly, the mammalian Toll-
like receptor (TLR) was shown to activate the NF-KB pathway, a key signaling 
pathway involved in a host of inflammatory responses (Medzhitov and Janeway, 
1997). Subsequently, it was determined that it was a mutation in a member of the 
TLR family, TLR4, that accounted for the lack of response to the bacterial cell wall 
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component lipopolysaccharide (LPS) in two strains of mice that had been noted for 
this defect (Poltorak et al., 1998). Together, these discoveries demonstrated that 
the immune system recognizes microbial products to distinguish self from non-self. 
It is now known that most mammalian species express between 10-15 
distinct TLR members on the plasma membrane and within endocytic 
compartments of specialized cell types (Akira et al., 2006; Iwasaki and Medzhitov, 
2004). These receptors recognize a broad array of pathogenic features including 
LPS, peptidoglycan, zymosan, flagellin, ssRNA, CpG DNA and profilin (Takeda and 
Akira, 2007). Such TLR ligands are similar in that they are not present in their 
metazoan hosts, thus making receptor ligation a signal of pathogenic threat. Just as 
importantly, the ligands are essential to the function of the pathogen, making it 
difficult for the forces of natural selection to significantly alter them to evade 
detection within the host. (It should be noted that this is now somewhat of an 
oversimplification since not all foreign species are pathogens (e.g. gut flora) and 
more recent studies have associated certain types of TLR signaling with host 
homeostasis (Lee et al., 2006; Rakoff-Nahoum et al., 2004)). 
The PRRs of the innate immune system are now known to extend beyond 
the prototypical TLR family. TLRs are transmembrane proteins that initiate 
signaling from the extracellular space as well as from within endosomal 
compartments. It is becoming clear that lectins may play a similar role. Dectin-1, 
a C-type lectin, is similar to TLRs in that it initiates inflammatory signaling 
pathways (Rogers et al., 2005) but different in that it is also a endocytic receptor 
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(Herre et al., 2004). There are also a variety of cytosolic PRRs capable of detecting 
pathogens from within the topologically distinct intracellular space. These 
receptors include Nod/Nod2, RIG-1, and the ISD sensor which recognize 
peptidoglycans, cytosolic viral RNA, and cytosolic viral DNA respectively (Palm 
and Medzhitov, 2009). 
In most tissue types, signaling induced by any of the panopoly of innate 
receptors of can lead to the recruitment of a rapid innate response. This is 
mediated by cell types such as neutrophils, monocytes, NK cells, eosinophils and 
basophils through the secretion of inflammatory cytokines, chemokines, and anti-
microbial peptides (Iwasaki and Medzhitov, 2004). DCs are unique, however, in 
that they do not merely contribute to this inflammatory response but initiate the 
adaptive response. PAMP recognition at the site of an infection is frequently 
accompanied by the internalization of pathogen-derived protein antigens by DCs. 
Through the processing of these antigens and the subsequent presentation of 
pathogen-derived peptides, DCs instruct the adaptive immune system on the 
identity of the threat, while using co-stimulatory molecules and cytokines to induce 
antigen-specific T cell expansion (Reis e Sousa, 2004; Trombetta and Mellman, 
2005). 
The Maturation Paradigm 
In response to TLR activation, DCs undergo a dramatic set of functional and 
morphological changes, termed maturation, that rapidly occur after contact with an 
11 
inflammatory stimulus (Trombetta and Mellman, 2005). Early evidence that DCs 
did not maintain a stable phenotype included the observation that while DCs 
greatly increased their ability to stimulate allogenic T cells after culture for 24 
hours, only freshly prepared cells could efficiently process and present specific 
antigens to T cell clones (Romani et al., 1989). It soon became clear that the 
increased ability to present antigen was largely due to a rapid and dramatic 
reorganization of cellular function. 
This cellular reorganization allows DCs to transition from specializing in 
antigen acquisition to specializing in antigen presentation (Reis e Sousa, 2006). 
Among the first changes that occurs is a rapid increase in macropinocytosis, 
followed by a nearly complete down-regulation (Garrett et al., 2000; West et al., 
2004). Newly stimulated DCs are in a potentially antigen-rich environment, and it 
has been suggested that increased antigen uptake would maximize the potential of 
initiating an immune response against the foreign target that activated the DC in the 
first place. The rapid down-regulation of macropinocytosis that follows has been 
used to support evidence for the so-called "snapshot hypothesis". This is the idea 
that because a DC ceases to take up new antigen after the initial stimulus, it 
presents a "snapshot" of the antigenic environment hours, or even days later 
(Ingulli et al., 1997; Villadangos et al., 2005). It has also been proposed that this 
prevents mature DCs from taking up self-antigens after activation, thus acting as a 
safeguard against potential autoimmunity (Thery and Amigorena, 2001). 
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Many other cellular changes occur as well. Essential to the maturing DCs 
cellular transformation is the reorganization of MHCII from the late endocytic 
compartments to the plasma membrane (Cella et al., 1997; Pierre et al., 1997). 
Activation leads to an initial burst in MHCII synthesis (Cella et al., 1997) and the 
formation of tubulo-vesicular structures highly enriched with peptide-MHC II 
complexes destined for the plasma membrane (Boes et al., 2002; Chow et al., 
2002). Another specialization leading to optimal antigen processing includes 
acidification of the lysosomal compartment leading to enhanced proteolysis 
(Trombetta et al., 2003). While peptide-MHCII complexes that reach the cell 
surface are rapidly internalized in immature DCs, these structures are stabilized on 
the surface of mature DCs due to the loss of ubiquitination of MHCII (Shin et al., 
2006; van Niel et al., 2006). This leads to a 10-fold increase in MHCII half-life and 
increases the likelihood of peptide-MHC complex recognition by T cells (Cella et 
al., 1997). 
Migration may or may not accompany DC maturation (Reis e Sousa, 2006). 
Both the spleen and lymph nodes contain populations of resident DCs that are in 
close proximity to T cells (Villadangos and Heath, 2005). However, peripheral DCs 
are stationed at sites including the skin, gut, lungs: the interface between the host 
and the external environment (Iwasaki, 2007). While their localization is critical 
to ensuring DCs detect pathogens early in the course of an infection, such 
positioning often leaves them a great distance from the T cells in the draining 
lymph nodes and spleen where they must traffic (Alvarez et al., 2008; Ingulli et al., 
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1997; Randolph et al., 2005). Thus, the maturation program includes up-regulation 
of proteolytic enzymes such as MMP-2 and MMP-9 that are necessary for migration 
through extracellular matrix-rich tissues and up-regulation of CCR7, a key 
chemokine receptor responsible for DC tropism for the LN (Bonasio and von 
Andrian, 2006) 
Antigen Capture 
All eukaryotic cells demonstrate at least some form of endocytosis as 
internalization and recycling of plasma membrane components is essential to 
cellular homeostasis (Mellman, 1996). Specialized cell types within complex 
multicellular organisms use various forms of endocytosis to control a sweeping 
range of activities from neuronal transmission to host defense (Mellman, 1996). 
DCs are specialized in this latter function, as the first step in initiating an immune 
response is antigen capture (Trombetta and Mellman, 2005). 
DCs acquire both self and foreign antigens through one of several forms of 
endocytosis, most broadly divided into phagocytosis, the uptake of large particles 
(>0.5[jm), and pinocytosis, the uptake of fluids or solutes (Conner and Schmid, 
2003). While phagocytosis is only carried out by specialized cell types, DCs being 
among them, pinocytosis occurs in all cell types by one of several possible 
mechanisms. These include clathrin-mediated endocytosis, caveolae-mediated 
endocytosis, clathrin- and caveolae-independent endocytosis, and 
macropinocytosis (Conner and Schmid, 2003). Of these mechanisms, 
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phagocytosis, clathrin-mediated endocytosis and macropinocytosis have all been 
extensively examined in DCs and have been implicated in antigen presentation 
(Garrett et al., 2000; Sallusto et al., 1995; Savina and Amigorena, 2007). 
Antigen Capture: Phagocytosis 
Whenever the organism enjoys immunity, the introduction of 
infectious microbes is followed by the accumulation of mobile cells, 
of white corpuscles of the blood in particular which absorb the 
microbes and destroy them. The white corpuscles and the other cells 
capable of doing this have been designated 'phagocytes,' (i.e., 
devouring cells) and the whole function that ensures immunity has 
been given the name of 'phagocytosis' (Metchnikoff, 1908). 
These were the words of the Russian embryologist llya Metchnikoff as he 
accepted his Nobel Prize along with Paul Ehrlich in 1908. Years earlier, after 
observing what appeared to be ingested cells within sea star larvae, he successfully 
demonstrated these cells were capable of recognizing and internalizing foreign 
objects. He found that similar phagocytes existed in humans and began 
accumulating evidence that they played an important role in host defense (Stuart 
and Ezekowitz, 2005). His view proved to be remarkably prescient as specialized 
cells such as DCs, neutrophils, monocytes and macrophages employ phagocytosis 
when clearing pathogens and apoptotic cells or when remodeling tissue (Conner 
and Schmid, 2003). 
Phagocytosis typically proceeds after a specialized cell recognizes an 
appropriate ligand on the surface of a particle. Target recognition is possible 
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through one of two strategies. The first is through direct binding of a ligand by 
specific receptors. Examples include recognition of phosphatidyl serine on 
apoptotic cells by TIM-4 (Kobayashi et al., 2007; Miyanishi et al., 2007) or 
recognition of bacterial carbohydrates by C-type lectins (Figdor et al., 2002). The 
second strategy is through recognition of soluble pattern recognition receptors that 
have opsonized the target. This strategy, which effectively increases receptor 
diversity, includes recognition of IgG by the FcyR or complement by the 
complement receptor (Stuart and Ezekowitz, 2005). 
Interestingly, the mechanism of phagocytosis differs depending on the 
receptors that are engaged (Kerrigan and Brown, 2009). FcyR mediated 
phagocytosis of an opsonized particle engages a signaling cascade involving the 
small GTPases Rac1, Cdc42 and Rho (Cox et al., 1997; Garrett et al., 2000; Massol 
et al., 1998). This leads to an actin-dependent advance of plasma membrane over 
the surface of the particle, leading to further engagement of FcyRs and the 
continuing engulfment of the particle (Greenberg et al., 1990; Swanson, 2008). In 
contrast, the phagocytosis of complement-opsonized particles requires Rho but not 
Cdc42 and Rac1 (Caron and Hall, 1998). The actin-rich pseudopodia seen during 
FcyR-mediated phagocytosis particles are notably absent, and the resulting 
phagosome is also more spacious (Kerrigan and Brown, 2009). 
Through a series of fusion and maturation events, the newly formed 
organelle encasing the internalized particle progresses functionally and 
semantically from phagosome to phagolysosome (Garin et al., 2001). Especially in 
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macrophages, this compartment is specialized for the killing of pathogens (Stuart 
and Ezekowitz, 2005). Reactive oxygen species, formed by NADPH oxidase, 
participate in both the direct killing of pathogens and the activation of proteases 
which also contribute to pathogen destruction (Reeves et al., 2002). 
DCs use this same machinery to increase the efficiency of cross-presentation 
antigens on MHCI. The NADPH oxidase NOX2 is recruited to the phagosome, 
producing low levels of reactive oxygen species. While these levels are not 
optimal for pathogen killing, they lead to a sustained alkalinization of the 
phagosomal compartment. This leads to a less degradative environment, which is 
optimal for the formation MHCI-peptide complexes (Savina et al., 2006). 
DCs, now considered a quintessential phagocyte, were initially described as 
non-phagocytic (Steinman and Cohn, 1974). In fact what was observed was the 
modulation of DC phagocytosis that occurs after DC maturation. Freshly isolated 
cells were highly phagocytic, but lost this ability when put in culture (Reis e Sousa 
et al., 1993). Down-regulation of phagocytosis can also be induced after the 
introduction of inflammatory stimuli such as LPS or CpG DNA, both in vitro and in 
vivo (Garrett et al., 2000; Wilson et al., 2006). 
Antigen Capture: Macropinocytosis 
Macropinocytosis involves the uptake of large volumes of extracellular fluid 
by ruffles of plasma membrane extended via localized actin filament assembly 
(Swanson, 2008). While different from phagocytosis in that uptake is not directly 
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triggered by a particular ligand, the cellular machinery and regulation of 
macropinocytosis are otherwise quite similar. Despite the fact that there is 
relatively little evidence of its relevance in vivo, this form of antigen acquisition has 
been studied and modeled extensively in DCs (Sallusto et al., 1995; Steinman and 
Swanson, 1995). 
There are several reasons for this. First, while many cell types can be 
induced to perform macropinocytosis by the addition of specific factors such as 
PDGF or EGF, or by pathogens, initial studies showed that DCs are constitutively 
macropinocytic (Sallusto et al., 1995). Thus, it seems intuitive that DCs would use 
this method of antigen uptake to widely sample their environment under steady 
state conditions. 
Second, these cells are capable of taking up a volume of extracellular fluid 
comparable to the volume of the cell itself in approximately one hour (Sallusto et 
al., 1995). Because of the impressive endocytic rate and non-specificity, 
macropinocytosis is the most easily studied endocytic route in vitro. Antigen or 
endocytic tracers can be internalized by DCs in high quantities, simply by adding 
these reagents to tissue culture medium. 
Lastly, and perhaps most importantly, the macropinocytic rate is modulated 
by pathogen presence and inflammatory mediators (Falcone et al., 2006; Garrett et 
al., 2000; West et al., 2004). Immediately after DC activation with a variety of TLR 
stimuli, there is a transient burst of endocytic activity (West et al., 2004) followed 
by down-regulation, mediated at least in part by a reduction of the active form of 
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the Rho GTPase, Cdc42. (Garrett et al., 2000; Sallusto et al., 1995). Thus, the cell 
biology of DC macropinocytosis could be fit immediately into an immunological 
context: these cells efficiently take up antigen when they first encounter a 
pathogen, but then cease further antigen uptake, perhaps preventing autoimmunity 
(Reis e Sousa, 2006). 
Antigen Capture: Receptor/Clathrin Mediated Endocytosis 
All mammalian cells continuously use endocytic receptors, internalized via 
clathrin-coated pits, to recruit essential nutrients such as low-density lipoproteins 
and transferrin (Anderson etal., 1982; Dautry-Varsat et al., 1983). Specialized 
leukocytes such as DCs, macrophages and neutrophils use this pathway to 
internalize endocytic receptors along with their potentially antigen-rich ligands. 
There are increasing numbers of receptors that have been identified as 
physiologically relevant for the uptake of foreign and self-antigens via clathrin 
coated pits (Kerrigan and Brown, 2009). 
The FcyR and the mannose receptor were among the first endocytic 
receptors characterized in DCs (Steinman, 1991). The FcyR was shown to mediate 
the efficient uptake of antibody/antigen complexes (immune complexes), a 
physiologically relevant source of potential antigens (Esposito-Farese et al., 1995). 
Antigens internalized as immune complexes are presented with high efficiency on 
both MHCI and MHCII (Amigorena and Bonnerot, 1999; Regnault et al., 1999). 
The mannose receptor has been shown to be at least partially responsible for 
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uptake and presentation of model antigens such as OVA and HRP (Sallusto et al., 
1995; Tan et al., 1997). This receptor, a C-type lectin, is thought to be 
physiologically relevant for binding soluble self-glycoproteins as well as a variety of 
bacteria, viruses and fungi through recognition of pathogen-associated high 
mannose (Engering et al., 1997; Gazi and Martinez-Pomares, 2009; Sallusto et al., 
1995). 
The mannose receptor is part of a much larger family of C-type lectins, the 
largest family of endocytic receptors that has been characterized in DCs (Cambi 
and Figdor, 2005). Members of this family contain a highly conserved 
carbohydrate recognition domain (CRD) with a calcium binding pocket (Figdor et 
al., 2002). However, both the CRD and calcium-binding pocket have been shown 
to be non-functional in certain receptors that otherwise have high homology with 
other C-type lectin family members. In some cases these receptors have been 
shown to bind proteins or lipids (Kogelberg and Feizi, 2001). 
DEC-205 is a particularly well-characterized C-type lectin. Its subcellular 
trafficking to the lysosomal compartment and recycling to the plasma membrane is 
well established (Jiang et al., 1995; Mahnke et al., 2000). It has also been studied 
extensively in vivo. Model antigens conjugated to anti-DEC-205 antibodies have 
been used to show that antigens introduced in the absence of other stimuli lead to 
T cell unresponsiveness and deletion (Bonifaz et al., 2002; Hawiger et al., 2001). 
Still other studies have shown how similar antibodies can efficiently mediates 
presentation of HIV epitopes (Bozzacco et al., 2007). Despite this extensive 
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characterization and modeling as a potential vaccine target, its physiologic role is 
poorly understood. This may change as a recent study has indicated that it binds 
and facilitates the uptake of apoptotic and necrotic cells (Shrimpton et al., 2009). 
DCs express a variety of other C-type lectins as well. DC-SIGN has been 
noted for its ability to bind HIV, though like the mannose receptor it has also been 
shown to bind mannan (Engering et al., 2002b). Dectin-1 has been shown to bind 
P glucans, a component of fungal cell walls and the receptor can mediate uptake of 
a series of fungal species including C. albicans, S. cerevisiae and A. fumigatus 
(Herre et al., 2004). There are still a number of lectins such as Dectin-2 and DCIR 
that have no known physiologic ligands. 
A feature that these receptors share is that they are all internalized via 
clathrin-coated pits. Clathrin-mediated endocytosis involves the assembly of 
clathrin, adaptor and accessory proteins along the inner leaflet of the plasma 
membrane associated with the cytosolic domains of aggregated surface receptors 
and their ligands (Conner and Schmid, 2003). Receptors are aggregated into 
coated pits at concentrations approximately two orders of magnitude greater than 
in the rest of the plasma membrane (Pearse and Robinson, 1990). These networks 
of clathrin and accessory proteins lead to membrane bending and budding. The 
ultimate fission step involves the GTPase dynamin, which constricts the vesicle 
neck though the formation of a collar of interconnected dynamin rings (Hinshaw 
and Schmid, 1995). Additional forces may be provided by myosin and actin 
(Ungewickell and Hinrichsen, 2007). 
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After release into the cytoplasm, the newly internalized vesicles lose their 
coats, allowing them to fuse with the early endosome compartment. This 
compartment, a dynamic collection of vesicles and tubules, has been considered a 
location where cargo destined for degradation is separated from cargo destined for 
recycling (Mellman and Warren, 2000; Schmid et al., 1988; Seaman, 2008). 
Newer data suggests that the sorting event may actually occur during 
internalization as different receptors sort to distinct early endosomal compartments 
(Lakadamyali et al., 2006). 
Antigen Processing 
As outlined earlier, DCs initiate immune responses by presenting antigen to, 
and thus activating, naTve T cells (Banchereau and Steinman, 1998). However, the 
TCR, whose activation is the gateway to the entire array of effectors within the 
adaptive immune response, cannot recognize unprocessed antigens (Davis et al., 
1998). Activation occurs when small antigen-derived peptides are loaded onto 
MHC molecules within the organelles of an antigen-presenting cell and these 
complexes are trafficked to the plasma membrane to be made available for 
recognition (Davis et al., 1998; Trombetta and Mellman, 2005). 
There are two main classes of MHC molecules, MHCI and MHCII, which 
define the type of T cells that are activated. Virtually all cells are capable of 
loading antigens onto MHCI thus activating CD8+ T cells (though DCs are uniquely 
able to prime naive CD8 T cells). However, DCs are one of only a small group of 
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"professional antigen-presenting cells" which express MHCII and can therefore 
present antigens to CD4+ T cells (Trombetta and Mellman, 2005). 
The topological origin of an antigen broadly determines whether an antigen 
will be presented on MHCI or MHCII, and therefore the immune response that will 
be generated against this antigen (Trombetta and Mellman, 2005). While there are 
many exceptions to this rule, some of which will be discussed, intracellular 
antigens are classically loaded on MHCI while extracellular antigens are presented 
on MHCII (Ackerman and Cresswell, 2004; Trombetta and Mellman, 2005; Wilson 
and Villadangos, 2005) 
The majority of antigens that are endocytosed are trafficked to the lysosomal 
compartment. In most cell types this is a terminal, degradative compartment and 
any potential antigenic epitopes would be lost. Rather DCs have modified MHCII 
rich lysosomes that are optimized for antigen loading (Chow and Mellman, 2005; 
Kleijmeer et al., 1997). Instead of hydrolyzing proteins to individual amino acids, 
DCs relatively mild lysosomes generate peptides for loading on MHCII (Delamarre 
et al., 2005). 
MHCII follows its own path to the lysosomes after it is synthesized on rough 
ER so it can bind newly generated antigenic peptides. Newly synthesized MHCII is 
folded in the ER along with the chaperone, invariant chain (Cresswell, 1994; 
Trombetta and Mellman, 2005). The invariant chain has at least two main tasks. 
The first is trafficking MHCII to the endocytic compartment, where it can encounter 
antigen. The second function is performed by an invariant chain fragment called 
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CLIP. It sits in the peptide-binding groove where it protects MHCII from pre-mature 
loading of antigen (Bakke and Dobberstein, 1990; Cresswell, 1996). Peptide-
loading occurs with the assistance of HLA-DM, a MHC-like molecule that catalyzes 
the removal of CLIP from the peptide-binding groove (Denzin and Cresswell, 
1995). Once loaded with antigen, MHCII is trafficked to the plasma membrane in 
tubulovesicular structures (Boes et al., 2002; Chow et al., 2002). In immature DCs, 
MHCII is ubiquitinated and is rapidly internalized from the cell surface. In mature 
DCs, lack of ubiquitination leads to the stabilization of MHCII on the cell surface 
(Shin et al., 2006; van Niel et al., 2006). 
DCs are not unique in their expression of MHCI, which is present on the 
cell surface of virtually all nucleated cell types. However, presentation of antigens 
on MHCI by DCs is vital since they appear necessary to prime naive CD8+ T cells 
for the generation of a cytotoxic T cell response (Jung et al., 2002). The MHCI 
pathway is considered primarily a pathway of endogenous antigen presentation 
because the pathway originates in the cytosol (Pamer and Cresswell, 1998). 
Cytosolic proteins are fragmented by the proteasome and transported via TAP into 
the lumen of the ER where stable MHCI/peptide complexes are formed with the 
assistance of the chaperone tapasin, calreticulin and ERp57 (Peaper and Cresswell, 
2008). 
The topology of this antigen-processing pathway favors cytosolic proteins, 
which have access to the proteasome and TAP. However, because DCs must also 
induce immune responses against antigens that do not directly infect them, DCs 
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can also prime responses against exogenous antigens through a process called 
cross-presentation. Internalized antigens are introduced to the MHCI processing 
pathway (Kovacsovics-Bankowski and Rock, 1995; Norbury etal., 1995). Many 
mechanisms have been proposed including ER-phagosome fusion (Ackerman et al., 
2006; Guermonprez et al., 2003), transit of soluble antigen to the ER (Ackerman et 
al., 2005), loading of MHCI recycled from the cell surface (Gromme et al., 1999), 
various mechanisms of increased endosomal permeability (Reis e Sousa and 
Germain, 1995; Rodriguez et al., 1999), and even direct introduction through gap 
junctions (Neijssen et al., 2005). While many of these mechanisms may play a role 
under certain circumstances, many details of this pathway require further 
definition. 
The Route of Endocytosis Influences Antigen Presentation 
It is becoming clear that the relative efficiency of cross-presentation on 
MHCI versus direct presentation on MHCII can be determined in part by the 
endocytic receptor that internalizes the antigen. Long before the implications for 
antigen processing and presentation were known, it was clear that functionally 
distinct populations of endosomes existed and were involved in trafficking 
internalized cargo to specific intracellular sites (Hewlett et al., 1994; Schmid et al., 
1988). More recently it has been shown that distinct adaptors are involved in 
targeting different types of endocytic cargo (Robinson, 2004) and that sorting to 
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different populations of early endosomes occurs before the endosomes have even 
fully formed (Lakadamyali et al., 2006). 
There are a variety of different trafficking patterns revealed after the 
internalization of DC endocytic receptors. Like the contents of macropinosomes, 
the FcyR is delivered to the lysosomal compartment where it is degraded (Mellman 
et al., 1983; Sallusto et al., 1995). In contrast, DEC-205 and the mannose receptor 
are recycled. However, while the mannose receptor recycles directly from early 
endosomes (Burgdorf et al., 2007; Mahnke et al., 2000), DEC-205 delivers antigen 
deep into the late endosomal and lysosomal compartments before recycling (Jiang 
et al., 1995; Mahnke et al., 2000). Another C-type lecin, DC-SIGN localizes to the 
lysosomal compartment after internalization in immature DCs but stays in the early 
endosomal compartment in mature DCs (Engering et al., 2002b). 
W e now know that this differential localization of cargo can bias antigen 
processing and presentation preferentially towards MHCI or MHCII pathways 
(Burgdorf and Kurts, 2008). Antigen targeted to late endosomes, either through 
macropinocytosis, or through late endosome-targeted liposomes is more efficiently 
presented on MHCII (Belizaire and Unanue, 2009; Burgdorf et al., 2007). In 
contrast, antigen targeted to early endosomes by the mannose receptor, transferrin 
receptor or early endosome-targeted liposomes is most efficiently targeted on 
MHCI (Belizaire and Unanue, 2009; Burgdorf et al., 2007; Burgdorf et al., 2008). 
It is no surprise that antigens delivered to an MHCII loading compartment would be 
better presented on MHCII than antigens that stayed localized to early endosomes. 
26 
However, the precise mechanism of how localization to early endosomes is 
beneficial to MHCI presentation is still poorly defined, though loading of MHCI in 
the endosomal compartment has been reported (Burgdorf et al., 2008). 
DC Subsets 
DCs have often been discussed as if they are one specialized cell type (as 
they have been thus far). However, they are actually a heterogeneous group. 
There are at least six main populations of DCs that can be found in lymphatic 
tissues that can be distinguished by the pattern of various surface markers that they 
express (Vremec and Shortman, 1997). DCs of the lungs, skin, gut, and other 
mucosal surfaces also differ from one another in surface marker expression and 
phenotype. While these subsets all present peptide antigens to T cells on MHCI 
and MHCII, it is becoming clear that they play different roles and preferentially 
initiate different types of immune responses (Heath et al., 2004). 
One DC subset, the plasmacytoid DC differs from the remaining subtypes to 
such an extent that it has earned its own subgroup, with the remaining DC subsets 
collectively termed "conventional DCs" (Villadangos and Young, 2008). 
Plasmacytoid DCs produce exceptionally high amounts of type I interferon upon 
recognizing viral pathogens (Colonna et al., 2004). However, they are relatively 
poor at taking up exogenous antigens (Villadangos and Young, 2008). While these 
cells play a vital role in the initiation of both innate and adaptive antiviral 
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responses (McKenna et al., 2005), the scope of this dissertation is concerned chiefly 
with the subsets grouped as "conventional DCs." 
Conventional DCs found in secondary lymphoid tissues can most broadly 
be divided into migratory DCs and resident DCs. Migratory DCs reside in 
peripheral tissues under steady state conditions and travel through lymphatics to 
reach the local draining lymph nodes where they are able to present peripheral 
antigens (Randolph et al., 2005). Migration can be induced when these DCs come 
into contact with inflammatory stimuli, though migration also occurs under steady 
state conditions (Wilson et al., 2003). In contrast, resident DCs reside in the LNs 
and spleen without having resided in peripheral tissues (Wilson et al., 2003). 
The functional importance of having DCs present in spatially distinct 
locations has been explored. One implication is that there are two waves of 
antigen presentation when an inflammatory response is initiated in the periphery. 
The first wave is provided by resident DCs as they sample antigens draining from 
the periphery through the afferent lymphatics. The second wave is supplied by 
migratory DCs when they arrive in the LN up to 24 hours later (Itano et al., 2003). 
Other studies have shown that resident DCs can present antigens that are 
transferred to them directly by migratory DCs (Allan et al., 2003). The mechanism 
of this transfer has not been determined (Carbone et al., 2004). 
Surface expression of CD8aa homodimer has been helpful in the further 
classification of murine DC subsets. While this surface marker has no known 
function in DCs, it has been used to separate resident splenic DCs into two main 
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groups, CD8a+ DCs and CD8a- DCs (Shortman and Liu, 2002). CD8a+ DCs are 
superior at cross-presentation and the presentation of cellular antigens on both 
MHCI and MHCII. (den Haan et al., 2000; Heath et al., 2004). 
Initial studies suggested that this was due to the superior phagocytic 
abilities of CD8a+ DCs (Schulz and Reis e Sousa, 2002) or an increased ability to 
internalize dying cells (lyoda et al., 2002). However, more recent work has 
suggested that antigen capture alone cannot explain the difference (Schnorrer et al., 
2006). Gene expression profiles show that CD8a+ DCs are skewed towards the 
expression of proteins required for MHCI presentation such as TAP, ERAAP, tapasin 
and ERp57. CD8a- DCs in turn, are skewed towards expressing cathepsins, GILT, 
and H2-DM, all essential for MHCII presentation (Dudziak et al., 2007). These 
subsets also differ in the expression of endocytic receptors, such as DEC-205 and 
DCIR2(Dudziak et al., 2007). Differential expression of these and other receptors 
may provide DCs with both specificity in the pathogens they internalize as well the 
optimal trafficking of antigens to ideal processing compartments. 
Summary 
DCs play a fundamental role in initiating and directing adaptive immune 
responses. They widely sample their environment using several methods of 
endocytosis, then process and present peptide antigens to T cells. DC maturation, 
induced by pathogenic or endogenous stimuli, is the dramatic set of functional and 
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morphologic changes that allows these cells to present antigens in the optimal co-
stimulatory context. 
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Can mature DCs acquire and present new antigens? 
Largely because macropinocytosis and phagocytosis are greatly diminished 
in mature cells in vitro (Garrett et al., 2000; Reis e Sousa et al., 1993; Sallusto et al., 
1995; West et al., 2004), the idea that immature DCs accumulate antigen while 
mature DCs present antigen is uniformly accepted (Banchereau and Steinman, 
1998; Reis e Sousa, 2006). The idea has often been invoked to explain how DCs 
present pathogens acquired at the time of activation, while avoiding presentation of 
self-antigens encountered prior to or following pathogen encounter (Reis e Sousa, 
2006; Thery and Amigorena, 2001) . 
However, the cell biology of DCs suggests that the regulation of antigen 
capture and presentation may be more complex. First, mature DCs continue to 
form clathrin-coated vesicles (Garrett et al., 2000), suggesting that the 
internalization of selected surface molecules may still occur. Indeed, the 
internalization of MHCII ceases in mature DCs not because of any universal down-
regulation of clathrin-mediated endocytosis, but because of a down-regulation of 
MHCII specific ubiquitin targeting. An artificial restoration of ubiquitination of the 
MHCII p chain leads to efficient internalization (Shin et al., 2006). In addition, 
mature DCs have been reported to internalize immune complexes in vitro, though 
the implications for presentation on MHCII was not assessed (Gil-Torregrosa et al., 
2004). Together these findings indicate that receptor-mediated endocytosis of 
antigen by mature DCs was in need of direct analysis. 
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There have been occasional reports of mature DCs presenting newly 
acquired antigens in the literature. One study showed that mature Langerhans cells 
can acquire and present new antigens in vivo but not in vitro (Ruedl et al., 2001). 
Another study showed that DCs matured by CD40 ligation present antigen when 
matured by a particular stimulus (Nayak et al., 2006). However, they have failed to 
address the mechanism of presentation, or the substantial body of literature that 
supports the contrary model. These reports remain unconfirmed. 
Here we formally test the widely accepted premise that mature DCs are 
unable to acquire and present new antigens. Most studies of endocytosis in DCs 
have involved exposing cells to high concentration of antigens or endocytic tracers 
taken up primariy by macropinocytosis. While it is clear that mature DCs lose the 
ability to present such antigens (Garrett et al., 2000), it is unclear whether antigen 
could be efficiently internalized by endocytic receptors, and if so, whether the 
antigen could then be processed and presented. 
W e therefore characterized the ability of mature DCs to internalize and 
present antigens using Fey receptors (FcyR) and the decalectin DEC-205 as model 
endocytic receptors, each having been documented to enable presentation on 
MHCI and MHCII (Amigorena and Bonnerot, 1999; Jiang etal., 1995; Regnault et 
al., 1999). 
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Specific Aims of This Study 
1) Characterize the ability of mature DCs to capture and internalize antigens 
targeted to the DEC-205 and FcyR. 
2) Determine the subcellular trafficking of antigens targeted to DEC-205 and the 
FcyR. 
3) Determine whether receptor-targeted antigens are presented to T cells, both in 
vitro and in vivo. 
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Chapter 2: Internalization and Trafficking of Antigen by the FcyR 
and DEC-205 in Mature DCs 
Introduction 
W e first set out to determine whether mature DCs continue to internalize 
endocytic receptors. While the modulation of macropinocytosis is controlled by 
RhoGTPases (Nobes and Marsh, 2000), there has been no similar mechanism 
described to explain how uptake via endocytic receptor might also be down-
regulated. Instead, reduced surface expression of receptors has been proposed as a 
mechanism to prevent antigen uptake by mature DCs (Thery and Amigorena, 2001) 
though this has never been rigorously examined. W e therefore decided to closely 
examine the surface expression and endocytic function of two well-characterized 
endocytic receptors, DEC-205 and the FcyR. 
W e first chose to examine the FcyR because of it's known physiologic 
importance (Guyre et al., 1997) and well characterized ability to present antigens 
derived from internalized immune complexes on both MHC I and MHC II (Machy 
et al., 2000; Regnault et al., 1999). Unlike other receptors of the immune system, 
which recognize conserved features of pathogens, or lipids associated with cell 
death, FcRs are rather unique in that they bind antibodies, which are in turn 
capable of binding virtually any antigen. 
FcRs are composed of extracellular alpha chains that determine specificity 
for a particular class of Ig, and cytosolic signal tranduction subunits that determine 
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downstream signaling (Amigorena and Bonnerot, 1999). These signaling units are 
known as ITAMs and ITIMS, and are capable of initiating activating or inhibitory 
signals respectively. They are nearly identical to the signaling motifs associated 
with activation of B cell receptors and T cell receptors. The activating signals 
associated with ITAMs are also associated with internalization, vital for uptake and 
presentation of immune complexes by DCs (Daeron, 1997). 
FcyRs can be broadly classified into two groups: high and low affinity. Only 
high affinity FcyRs are able to bind monomeric Ig. Low affinity FcyRs bind 
monomeric Ig with negligible affinity, yet efficiently bind multivalent complexes 
(Hulett and Hogarth, 1994). It should be noted that both high and low affinity 
FcyRs must be aggregated to be activated. To this end, monomeric Ig binds high 
affinity receptors first, which are then complexed by antigen. Low affinity 
receptors, however, must bind antibody-antigen complexes that have been pre-
formed. In our study, by using immune complexes to probe endocytic function of 
FcyRs, we would be primarily probing the function of FcyRlII as the receptor is low 
affinity. Notably, since FcyRlII also has an ITAM, it is capable of endocytosis 
(Daeron, 1997). 
The other receptor that we chose to examine was DEC-205. This endocytic 
receptor is a member of the mannose receptor family, and is expressed on 
Langerhans cells, BMDCs and CD8a+ splenic DCs. DEC-205 contains ten 
external, contiguous, C-type lectin domains (Inaba et al., 1995). Interestingly, none 
of these ten domains contain known amino acid sequences thought to be necessary 
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for binding carbohydrates (Figdor et al., 2002). No natural ligand had been 
suggested in the literature until recently. 
While the first evidence was reported in 2003 (Small and Kraal, 2003), a 
more recent report supports the hypothesis that DEC-205 binds proteins associated 
with apoptotic and necrotic cells (Shrimpton et al., 2009). The authors of this 
report used a panel of IgG fusion proteins that included the various extracellular 
domains of the DEC-205 receptor. This panel was used to probe for potential DEC-
205 ligands. Their results suggested that C-type lectin domains 3&4 and 9&10, 
bind ligands expressed by cells only after they were subjected to insults that led to 
apoptosis or necrosis. Thus, there is evidence accumulating that the physiologic 
role for DEC-205 is the uptake of self-antigen. Whether this leads to tolerance or 
immunity depends on the associated inflammatory signals (Hawiger et al., 2001; 
Shrimpton et al., 2009). 
The cell biological fate of antigens bound by DEC-205 as well as the 
immune responses directed against such antigens have been determined by using 
monoclonal antibodies as surrogate ligands (Bonifaz et al., 2002; Hawiger et al., 
2001; Mahnke et al., 2000). Antigen endocytosed via DEC-205 is trafficked to late 
endosomes and lysosomes. The receptor is then rapidly recycled back to the 
plasma membrane where it is available for further rounds of antigen capture 
(Mahnke et al., 2000). Internalized antigen is processed for efficient presentation 
on both MHC class II and MHC class I molecules (Bonifaz et al., 2002; Jiang et al., 
1995). 
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Whether or not the FcyR, DEC-205 or other endocytic receptors continue to 
function in mature DCs has not been closely examined. Down-regulation of both 
macropinocytosis and surface expression of endocytic receptors have been 
identified as a major means of restricting antigen presentation to antigens 
encountered by immature DCs (Reis e Sousa, 2006; Thery and Amigorena, 2001). 
However, in most cells types studied, DEC-205 expression has actually been 
reported to be higher in mature DCs than in immature DCs (Butler et al., 2007; 
Engering et al., 2002a). One study of human monocyte derived DCs showed that 
DEC-205 was not internalized in mature DCs (Butler et al., 2007). However, no 
mechanism was reported to account for this, and this result has not been reported 
in other types of DCs. 
There has also been fairly little work on immune complex internalization by 
mature DCs. FcyR expression is lower in mature DCs than immature DCs (Regnault 
et al., 1999; Sallusto et al., 1995), though the implications for immune complex 
internalization are not known. While immune complex internalization by mature 
cells has been documented, presentation of antigen on MHCII has not been 
examined (Gil-Torregrosa et al., 2004). 
Unlike receptor-mediated endocytosis, the modulation of phagocytosis with 
maturation is well documented. Most reports have shown that phagocytosis is 
significantly down-regulated in mature DCs. In fact, DCs were initially shown to 
be non-phagocytic (Steinman and Cohn, 1974). It was later determined that these 
cells were proficient phagocytes when freshly harvested but that the cells down-
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regulated phagocytosis when put into culture (Reis e Sousa et al., 1993). Cells 
matured by this method were unable to take up neither opsonized nor unopsonized 
targets (Steinman and Swanson, 1995). 
Interestingly, in studies that examined phagocytosis after the application of 
inflammatory stimuli, the results are less clear-cut. DCs matured by LPS were 
shown to down-regulate uptake of bacteria (Garrett et al., 2000). Another study 
showed that LPS, CpG DNA and poly l:C all lead to substantial down-regulation of 
latex bead uptake in vivo (Wilson et al., 2006). However, more recently it was 
shown that neither CD40 nor LPS inhibited uptake of iron oxide particles in vitro 
(Nayak et al., 2006). W e therefore decided that it would be appropriate to confirm 
that inflammatory stimuli inhibit phagocytosis in our system and if so, to determine 
whether signaling induced by FcyR ligation could overcome such blockade. 
38 
Results 
Surface Expression of FcyR and DEC-205 on Immature and Mature DCs 
First, we confirmed that the FcyR and DEC-205 were present on mature 
DCs. As we ultimately intended to use both BMDCs as well as DCs derived from 
lymphatic tissue, we tested DCs from these various sources after maturation with 
LPS. Studies of DCs in culture systems show that DCs complete the maturation 
program after approximately 20 hours (Garrett et al., 2000; Mellman et al., 1998). 
Studies looking at maturation in vivo have been complicated by the disappearance 
of DCs and by the reappearance of immature DCs at later time points (De Smedt et 
al., 1996). Therefore, recent studies assessing the antigen presentation properties of 
mature DCs are typically performed only 9 hours after the inflammatory stimulus 
(Young et al., 2007). 
W e monitored FcyR expression before and after maturation using the 
monoclonal antibody 24G2. This antibody has specificity for both FcyRII and 
FcyRIII. As in previous studies (Regnault et al., 1999; Sallusto et al., 1995), we 
found that the FcyRII/lll was down-regulated slightly in BMDCs upon maturation 
(Fig. 1 A). This effect was must more modest in splenic DCs (Fig. 1B). In contrast, 
DEC-205 was highly up-regulated during maturation by BMDCs (Fig. 1 A), but was 
relatively unchanged upon maturation by splenic DCs (Fig. 1B). 
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Internalization of Immune Complexes and Anti-DEC-205 Antibody in Immature 
and Mature DCs 
Our initial aim was to determine if receptor-mediated uptake continues in 
mature DCs after macropinocytosis has ceased. W e therefore confirmed that the 
maturation conditions that we chose indeed led to the down-regulation of 
macropinocytosis, indicated by the lack of uptake of soluble OVA (Fig. 2). This is 
in agreement with more extensive studies (Garrett et al., 2000; Sallusto et al., 
1995). W e elected to use down-regulation of macropinocytosis as a marker of 
maturation for future experiments, both to ensure that maturation was complete 
and that uptake of receptor-targeted ligands was not occurring through fluid phase 
uptake. 
W e next sought to determine whether immune complexes (ICs) and anti-
DEC-205 antibody were internalized by mature BMDCs. To quantitatively measure 
internalization we turned to flow cytometry. ICs were generated from HRP and 
rabbit-anti-HRP antibodies. These were bound to the surface of mature and 
immature DCs at 4° C. After 30 min of incubation at 37° C (or at 4° C as a control), 
immune complexes remaining on the cell surface were detected with an anti-rabbit 
antibody. At this time point while the total signal from ICs remained stable, both 
mature and immature DCs had barely detectable levels of surface ICs (Fig. 3A). 
This indicates that nearly 100% of the immune complexes had been internalized 
after 30 min. 
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W e used a different assay to detect internalization of DEC-205. After 
binding anti-DEC-205 antibody to the surface of immature and mature cells, we 
incubated the cells at 37° C or 4° C. After 30 min we incubated the cells in an 
acetic acid buffer to strip off remaining surface antibodies. Only internalized 
antibody would be protected. A control wash in PBS was also used so that the 
total amount of antibody that had bound the cells could be measured. The assay 
showed that virtually all of the DEC-205 antibody was protected from the acid 
wash after the 37° C incubation (Fig. 3B). Thus, the internalization of DEC-205 was 
essentially complete by both mature and immature DCs. W e concluded that unlike 
macropinocytosis, receptor-mediated endocytosis is not down-regulated by 
maturation. 
Localization of Internalized Immune Complexes and anti-DEC-205 Antibody 
Next, to confirm internalization, and to determine where captured antigen is 
trafficked, we used confocal microscopy. Because such assays rely on the analysis 
of individual cells, we felt that it was necessary to ensure that we were not 
analyzing a minor contaminating population of immature cells. Therefore, we used 
FACS to sort a highly purified population of cells that was CD86 high and could 
not take up soluble OVA. This technique allowed us to ensure that 1) these cells 
were mature by two independent criteria and 2) any uptake was indeed via a 
receptor-mediated pathway (Fig. 4). 
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After binding fluorescently-labeled ICs or anti-DEC-205 antibody to DCs at 
4° C, the cells were warmed to 37° C and were fixed at various time points. W e 
found that most ICs reached H-2M+ late endosomal/lysosomal compartments of 
mature DCs by 2 hours after internalization (Fig. 5A). In contrast, anti-DEC-205 
antibodies partially localized to the lysosomal compartment after only 15 min, but 
exhibited a diffuse pattern after 2 hours, suggesting their degradation in or recycling 
from the lysosomal compartment (Fig. 5B). 
This data is consistent with reports in other cell types. The FcyR has been 
shown to be degraded in the lysosomal compartment of macrophages after 
trafficking from the plasma membrane (Mellman et al., 1983). In contrast, DEC-
205 recycling is in agreement with previous analysis of DEC-205 dynamics in 
transfected cells (Mahnke et al., 2000). 
Next, we moved to immuno-electron microscopy to confirm the localization 
of internalized immune complexes and anti-DEC-205 antibodies. Fusion with the 
lysosomal compartment would be consistent with what has been observed in 
immature DCs(Chow and Mellman, 2005). W e found that 60 min after 
internalization -50% of immune complex-gold (Fig. 6) and anti-DEC-205-gold (Fig. 
7) were detected in LAMP-2+ lysosomal compartments. Thus, mature DCs can 
efficiently internalize and deliver receptor-bound antigen to late endocytic 
compartments, where MHCII peptide complexes are known to form in immature or 
maturing DCs. 
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Phagocytosis of IgG Coated Latex Beads by Mature DCs 
Phagocytosis is a physiologically important route of entry that permits DCs 
to present pathogen-derived antigens with high efficiency on MHCI and MHCII. It 
is also one that is down regulated during maturation due in part to a decrease in 
active, GTP-loaded Cdc42 (Cox et al., 1997; Garrett et al., 2000). Pathogens such 
as S. typhimurium can overcome this block by injecting a guanine nucleotide 
exchanger for Cdc42 (Garrett et al., 2000), suggesting that phagocytosis might also 
be triggered in mature DCs by coupling the phagocytic ligand to an appropriate 
signaling receptor. W e hypothesized that the FcyR could be such a receptor as the 
C-terminal domain contains an ITAM that participates in FcR-mediated 
phagocytosis (Swanson, 2008). W e therefore tested whether FcyR cross-linking 
could trigger phagocytosis in mature DCs. 
As expected, both BSA and IgG-coated latex beads were avidly taken up by 
immature DCs and targeted to the lysosomes (Fig. 8A). BSA-coated beads were 
frequently found to be associated with mature DCs, but these were not 
internalized, as shown by confocal microscopy (Fig. 8A). This confirms previous 
findings that constitutive phagocytosis of untargeted particles is down-regulated by 
DC maturation (Garrett et al., 2000; Reis e Sousa et al., 1993; Wilson et al., 2006). 
In contrast, mature DCs internalized IgG-coated beads with comparable efficiency 
to immature DCs. As with immature DCs, IgG coated beads were trafficked by 
mature DCs to lysosomal compartments (Fig. 8A). W e quantified this by 
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examining at least 90 randomly chosen cells from each condition, using lysosomal 
localization as an unequivocal marker of internalization (Fig. 8B). 
These data indicate that while mature DCs down regulate non-specific forms 
of endocytosis (both macropinocytosis and phagocytosis), receptor-mediated 
endocytosis and phagocytosis remain efficient routes of uptake. Internalized cargo 
is trafficked to the lysosomal compartment where it would theoretically be 
available to antigen-processing machinery. 
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Discussion 
W e have demonstrated that in contrast to the prevailing view that mature 
DCs lose the ability to acquire new antigens, these cells can continue to efficiently 
capture and internalize antigens using the FcyR and DEC-205 receptors and traffic 
these antigens to the lysosomal compartment. 
Mature BMDCs efficiently shut down macropinocytosis after maturation 
(Fig. 2). This fits conveniently with a model of mature DCs as antigen presenters, 
wary of taking up new antigens lest they present "self" as "foreign" and initiate 
autoimmunity (Reis e Sousa, 2006; Thery and Amigorena, 2001). MHCII, arguably 
the most important of the DC surface molecules, appears frozen on the surface of 
mature DCs. However, the plasma membrane of the mature DC is much more 
dynamic than this molecule would suggest. Unlike MHCII which has surface 
expression controlled by ubiquitination (Shin etal., 2006; van Niel et al., 2006), 
neither DEC-205 nor the FcyR have maturation-linked mechanisms regulating 
surface internalization. 
The FcyR has a well-established physiologic role in both clearing immune 
complexes and presenting antigens (Takai, 2005). Interestingly, the receptor is 
slightly down-regulated upon maturation (Fig. 1). However, this did not prevent it 
from efficiently mediating the internalization of immune complexes and opsonized 
particles (Fig. 3, Fig 5, Fig. 7 & Fig. 8). 
DEC-205 has a less established physiologic function, though it has been 
implicated as playing a role in the uptake of apoptotic cells (Shrimpton et al., 
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2009). Its up-regulation during maturation (Fig. 1) makes it an intriguing choice for 
further study. It is not immediately apparent why it would be advantageous for a 
mature DC to have the increased ability to take up what may be primarily self-
antigens. 
Most studies of DC phagocytosis fail to make distinctions among the several 
mechanisms of phagocytosis, only some of which are well-characterized (Kerrigan 
and Brown, 2009). The constitutive phagocytosis that immature DCs display does 
not to require interaction with an endocytic receptor and is functionally similar to 
macropinocytosis. Immature DCs are capable of internalizing even large particles 
through this mechanism (Fig. 8). However, when macropinocytosis is down-
regulated as a consequence of maturation, so is the non-specific internalization of 
large particles. 
During FcyR-mediated phagocytosis, binding to IgG leads to signaling events 
initiated by the cytoplasmic domains of the FcyR which results in the receptor-
guided advance of membrane and cytoskeleton over the surface of the particle 
(Swanson, 2008). Our data indicate that FcyR-mediated phagocytosis can occur 
long after the maturation stimulus (Fig. 8). While there is contradictory literature 
showing that even opsonized particles are not taken up by mature DCs, all of this 
work was done with cells matured by dissociation from lymphatic tissue (Steinman 
and Swanson, 1995). More work needs to be done to explore whether different 
modes of maturation lead to differential regulation of antigen uptake. 
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It seems that while immature cells have at least two distinct mechanisms of 
phagocytosis at their disposal, mature DCs have only receptor-mediated 
phagocytosis. Thus, DCs are selective in modulating cellular activities in response 
to maturation. They specifically down-regulate non-specific uptake, while leaving 
intact the internalization and trafficking of surface receptors. However, the 
consequences of such internalization in a cell type presumed functionally 
incapable of further antigen processing remains unclear. 
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Materials and Methods 
Generation of BMDCs 
C57BL/6J mice were purchased from The Jackson Laboratory. BMDCs were 
prepared by harvesting bone marrow from 6-12 weeks in age. Red blood cells 
were lysed in ACK lysis buffer (Invitrogen). Stem cells were isolated and incubated 
with anti-CD8 (TIB211), anti-CD4 (GK1.5), anti-CD45R (B220) and anti-MHCII 
(TIB120) before incubation at 37° C with rabbit complement (Rockland 
Immunochemicals). Cells were resuspended at 10e6 cells/ml in tissue culture 
medium. This medium contained RPMI 1640 (Invitrogen) supplemented with 5% 
FBS 2mM L-glutamine, 20|jg/ml gentamicin, and supernatant from J558L cells 
transfected with murine GM-CSF cDNA. In some experiments 10 ng/ml 
recombinant GMCSF (Peprotech) and 10 ng/ml IL-4 (Peprotech) was used with 
equivalent results. Resuspended cells were plated at a concentration of 10e6 cells 
per well in 24 well plates (Corning). Cells were grown at 37° C in 7% C02 and 
media was changed every 2 days. Immature DCs were used on day 6 of culture. 
Mature DCs were stimulated with 50 ng/ml of LPS 20 hours before harvest. 
Generation of Splenic DCs. 
Splenic and lymph node DCs were obtained from the spleens or lymph nodes of 
mice that had been injected IP with 3 |jg of LPS (mature) or with PBS (immature). 
Tissue was cut into small pieces and incubated at 37° C with Liberase Blendzyme II 
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and DNase (Invitrogen) before cells were dissociated by passage through a 70 [jm 
cell strainer (BD). When indicated, cells were purified with CD11c+ cell isolation 
beads after harvest (Miltenyi). 
Cell Sorting 
When indicated, cells were sorted before use. DCs were pulsed with OVA-Alexa-
647, washed, and subsequently stained with anti-CD11c, and anti-CD86. Cells 
were washed and resuspended in PBS supplemented with 0.5% BSA at a 
concentration of 20e6 cells/ml. Cell were passed through a 70pm cell strainer 
sorted using a BD FACSVantage SE, BD FACSAria, or a Dako MoFlo. 
Mature DCs were gated on CD11c+, CD86 high, soluble OVA-Alexa-647 low 
cells. Immature DCs were gated on CD11 c+ CD86 low, soluble OVA intermediate 
to high cells. 
Confocal Microscopy 
BMDCs were seeded on alcian blue-coated coverslips at 37° C in serum free media 
for 15 min. Cells were washed with PBS and fixed with 4 % paraformaldehyde for 
20 min at room temperature. Cell were blocked and permeabilized in a buffer 
containing 10% goat serum, 10mM Hepes, pH 7.4, 10 mM glycine and 0.05% 
saponin. Cells were stained with a rabbit anti-H-2M polyclonal antibody and anti-
MHCII antibody (K4H7) for 30 min. Cells were washed, then stained with anti-
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mouse-Alexa633 or anti-rabbit-Alexa555. Imaging was performed with a Zeiss LSM 
510 or Leica SP5 confocal microscope. 
Electron Microscopy 
Cells were labeled at 4° C with anti-DEC-205 biotin or anti-HRP-biotin/HRP 
immune complexes for 15 min. Cells were washed and labeled with 10 nm anti-
biotin-gold (Aurion). Cells were fixed in suspension in 4 % PFA, 0.25M HEPES 
buffer, pH 7.4 for 1 h at room temp. Concentration of PFA was increased to 8% in 
the same buffer and cells were stored overnight. Cells were then embedded in 
10% gelatin, infiltrated in 2.3 M sucrose in PBS and frozen in liquid nitrogen. 70 
nm cross-sections were cut on a Leica Ultracut cryo-microtome and collected on 
100 hexagonal nickel grids coated with formvar and carbon. Sections were labeled 
with anti-MHC class II (TIB-120) or anti-LAMP-2 followed by rabbit anti-rat 
antibody and 5 nm protein A gold, then incubated with 1.8% methyl cellulose and 
0.5% uranyl acetate and air dried. They were examined with a Tecnai 12 Biotwin 
electron microscope (FEI). Images were recorded using a Morada CCD camera 
(Olympus Soft Imaging Solutions). For quantitation approximately 30 images were 
taken at random. The percentage of DEC-205 gold or immune complex-gold 
contained within LAMP-2 or MHCII labeled structures were counted. 
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Flow Cytometry 
Cells were resuspended in PBS containing 0.5% BSA, stained for 15 min on ice 
with antibodies conjugated with FITC, PE or APC, then washed twice with buffer. 
The stained cells were fixed with 1% PFA, then subjected to flow cytometry (BD 
Canto-II, FACSCalibur, or Aria). The collected data were analyzed with Flowjo 
software. 
Endocytosis Assays 
HRP/anti-HRP immune complexes were made by incubating HRP (Sigma) with 
anti-HRP-FITC or anti-HRP-Cy5 Qackson ImmunoResearch Laboratories) at a 1:3 
molar ratio on ice for 30 min. To detect antibody internalization using an acid 
wash assay, cells that had previously been bound with anti-DEC-205-Alexa 488 
(Serotec) and incubated for 30 min at 37°C or 4°C were either incubated for 5 min 
in an acid buffer (0.2 M acetic acid, 0.15M NaCl, pH 3.0) to remove surface-bound 
antibodies or in PBS as control. 
Phagocytosis Assays 
1pm Fluoresbrite® yellow-green carboxylated latex microspheres (Polysciences 
Inc.) were coated overnight in 1mg/ml mouse IgG (Jackson ImmunoResearch 
Laboratories) or 1mg/ml BSA (Sigma) and washed 3 times in PBS before incubation 
with DCs at a concentration of 9.1 x107 beads/ml. 
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Antibodies 
Mouse IgG, anti-HRP-Cy5, anti-HRP-biotin were purchased from Jackson 
ImmunoResearch Laboratories. Anti-CD86-FITC/ PE/APC (GL1), anti-CD8a-PerCP 
(53-6.7), anti-CD45R-Pacific Blue (RA3-6B2), anti-CD11 c-PE-Cy5 (HL3), anti-
Fcyll/lll-PE (2.4G2), anti-MHCII (KH74) were purchased from BD. Anti-DEC-205-
Alexa 488 were purchased from Serotec. Anti-DEC-205-PE was purchased from 
Miltenyi. Anti-H-2M (Pierre et al., 1997) is rabbit polyclonal antibody. Anti-
MHCII (TIB-120) and anti-LAMP-2 were grown from hybridomas in the laboratory. 
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Figure 1 - Expression of DEC-205 and FCYRII/W by immature and mature DCs. 
(A) BMDCs were treated with 50 ng/ml of LPS on the 5th day of culture for 20 h 
or left untreated. They were stained with anti-DEC-205, anti-FcyRII/III or isotype 
control as well as anti-CD86 and anti-CD11c. In DEC-205 and FcyRII/lll plots, 
immature cells are gated on the CD11c+, CD86 low population while mature 
cells are gated on the CD11c+, CD86 high population. CD86 plots are gated on 
all CD11 c+ cells 
(B) Splenic DCs were derived from LPS treated (3 pg i.p.) or PBS treated control 
mice. 6 h after injection, spleens were harvested, and splenocytes isolated. Plots 
are gated on CD11c+ cells and CD8a+ or CD8a- populations as indicated. 
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Figure 2 - Mature DCs down-regulate macropinocytosis. 
BMDCs were treated with 50ng/ml of LPS on the 5th day of culture for 20 h or left 
untreated. Cells were incubated with OVA-Alexa-647 for 10 min at 37° C or on 
ice. Cells were washed, then stained for CD86 and CD11 c and were analyzed by 
flow cytometry. Histograms of immature DCs are gated on CD11C+ CD86 low 
cells. Histograms of mature DCS are gated on CD11 c+ CD86 high cells. 
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Figure 3 - Efficient internalization of immune complexes and anti-DEC-205 
antibody by mature DCs. 
(A) BMDCs were treated with 50 ng/ml of LPS for 20 h to induce maturation or 
left untreated. Cells were incubated with Cy5-labeled HRP/rabbit anti-HRP 
immune complexes (1 Ofjg/ml) for 15 min, then washed. Complexes remaining 
on the surface after 30 min of incubation at 4° C or 37° C were detected with 
Alexa488-labeled anti-rabbit IgG. Cells were labeled with anti-CD86 and 
anti-CD11c and were analyzed by flow cytometry. Histograms of immature 
cells are gated on CD86 low, CD11c+ cells. Histograms of mature cells are 
gated on CD86 high, CD11 c+ cells. 
(B) Immature or LPS-matured BMDCs were incubated with anti-DEC-205-
Alexa488 (5 pg/ml) for 15 min. Cells were washed and incubated for 30 min at 
4° C or at 37° C to allow for internalization. Antibodies remaining on the cell 
surface were removed by an acid buffer (internalized antibody is protected). 
Cells were labeled with anti-CD86 and anti-CD11c and were analyzed by flow 
cytometry. Histograms of immature cells are gated on CD86 low, CD11 c+ cells. 
Histograms of mature cells are gated on CD86 high, CD11c+ cells. 
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Pre-Sort Post-Sort 
Figure 4 - Sorting pure populations of immature and mature DCs. 
BMDCs were stimulated with 50 ng/ml of LPS for 20 h or left untreated. 
Immature and LPS-matured cells received a 10 min pulse with OVA-Alexa-647 
(0.5 pg/ml) to measure macropinocytosis, and were stained with anti-CD11c 
and anti-CD86. Cells were then sorted by CD86 surface expression and level 
of OVA uptake. Mature DCs met the criteria of being CD11 c+, CD86 high, 
and OVA-Alexa647 low. Immature DCs were CD11c+, CD86 low, and had 
internalized varied amounts of OVA. 
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anti-DEC-205 H-2M MHCII Merge 
Figure 5- Efficient internalization of ICs and anti-DEC-205 antibody by 
mature DCs. 
(A) LPS-matured BMDCs were sorted as in Fig. 4. They were then incu-
bated with FITC-labeled immune complexes (5 pg/ml) at 4° C for 15 min. 
Cells were washed, and incubated at 37° C for the indicated time to allow 
for internalization before fixation. They were labeled with anti-H-2M and 
anti-MHCIl and analyzed by confocal microscopy. 
(B) LPS-matured BMDCs were sorted as in Fig. 4. They were then incu-
bated with anti-DEC-205-Alexa488 (5pg/ml) at 4° C for 15 min. Cells 
were washed, and incubated at 37° C for the indicated time to allow for 
internalization before fixation. They were labeled with anti-H-2M and 
anti-MHCIl and analyzed by confocal microscopy. 
57 
B 
5 min 20 min 
CL £ CD 
E 
< T ro 







• LAMP (-) 
• LAMP (+) 
5 min 20 min 60 min 
(n=19) (n=23) (n=29) 
Figure 6- Trafficking of immune complexes to the lysosomal compartment. 
(A) LPS-matured BMDCs were sorted according to the criteria described in Fig 4. 
Cells were incubated with HRP/anti-HRP-biotin immune complexes (10 pg/ml) at 
4° C for 15 min, washed, then labeled with anti-biotin 10 nm gold at 4° C for 15 
additional min. Cells were washed again, and incubated at 37° C for the indi-
cated time to allow for internalization before fixation. Cryosections were labeled 
with anti-LAMP-2 and were examined by electron microscopy. 
(B) 30 random images were acquired of fields containing at least one immune 
complex-gold containing vesicle. These vesicles were identified as LAMP-2 
positive or negative compartments at 5 min, 20 min or 60 min after internaliza-
tion. 
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Figure 7 -Trafficking of anti-DEC-205 antibody to the lysosomal compartment. 
(A) LPS-matured BMDCs were sorted according to the criteria described in Fig 4. 
Cells were incubated with anti-DEC-205-biotin (5 |Jg/ml) at 4° C for 15 min, 
washed, then labeled with anti-biotin 10 nm gold at 4° C for 15 additional min. 
Cells were washed again, and incubated at 37° C for the indicated time to allow for 
internalization before fixation. Cryosections were labeled with anti-LAMP-2 and 
were examined by electron microscopy. 
(B) 30 random images were acquired of fields containing at least one DEC-205-gold 
containing vesicle. These vesicles were identified as LAMP-2 positive or negative 
compartments at 5 min, 20 min or 60 min after internalization. 
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Figure 8 - Efficient phagocytosis of IgG-coated latex beads by mature DCs. 
(A) Immature and LPS-matured BMDCs were incubated with IgG- or BSA-coated 
fluorescent beads, for 30 min at 37° C, washed, and chased for 15 min at 37° C. 
After pulse-chase, the cells were fixed, stained for the indicated markers, and 
analyzed by confocal microscopy. 
(B) At least 90 DCs from each condition were selected at random and examined 
for the presence of beads within H2-M+ compartments, thus confirming complete 
internalization. 
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Chapter 3: Antigen Processing and Presentation By Mature DCs 
Introduction 
The concept that mature DCs lose the ability to acquire, process and present 
new antigens has become part of the dendritic cell dogma (Reis e Sousa, 2006). It 
was long known that mature DCs were powerful antigen presenters yet quite weak 
at presenting newly encountered antigens (Romani et al., 1989; Steinman, 1991). 
As the cell biology of DC maturation was unraveled, several mechanisms emerged 
to explain this. First, the down-regulation of endocytosis that accompanies 
maturation was shown to be an important initial barrier (Banchereau and Steinman, 
1998; Wilson et al., 2006; Wilson and Villadangos, 2005). Next, MHCII synthesis 
is reduced in mature DCs (Cella et al., 1997; Pierre et al., 1997; Villadangos et al., 
2001; Young et al., 2007). Furthermore, as DCs mature, MHCII molecules are 
translocated from lysosomes to the plasma membrane, which greatly decreases 
acceptor MHCII for peptides that might be generated following residual antigen 
uptake (Sallusto and Lanzavecchia, 1994; Turley et al., 2000). 
A recent study by the Villadangos group attributed the lack of antigen 
presentation of mature DCs exclusively to reduced MHCII synthesis (Young et al., 
2007). While the authors acknowledged that macropinocytosis is shut down in 
mature DCs, they argued that antigen can still be delivered by pinocytosis, and that 
the antigen presentation ability of immature and pre-matured DCs can be 
compared using soluble antigens (Young et al., 2007). The uptake of endocytic 
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tracer appeared similar in both mature and immature DCs under the conditions that 
they used (Young et al., 2007). Still, since no analysis of subcellular targeting of 
antigen was done, it was not clear that the reduced presentation could be attributed 
purely to a reduction in MHCII synthesis. 
W e demonstrated in chapter 2 that mature DCs can continue to take up 
antigens by receptor-mediated endocytosis, and even transport these antigens to 
traditional antigen-processing compartments. W e therefore sought to target 
antigens to these receptors to test the ability of immature and pre-matured DCs to 
process and present newly internalized antigens. 
To do this we employed two independent methods. First, we chose to 
compare the ability of immature and mature DCs to present different forms of 
antigens to transgenic T cells. W e used a well-established system by which DCs 
are capable of internalizing, processing and presenting ovalbumin (OVA) on MHCI 
and MHCII to transgenic T cells (Robertson et al., 2000). 
To target antigens to the FcyR, we created immune complexes (ICs) by 
incubating soluble OVA protein with polyclonal rabbit anti-OVA antibodies (Fig. 
9B). Similar antigen-antibody complexes, composed of self or foreign antigens, are 
present under physiologic conditions in vivo (Takai, 2005). To target the OVA 
protein to DEC-205 we generated chimeric anti-DEC-205 antibodies that had the 
antigenic peptides recognized by OT.I and OT.II transgenic T cells engineered into 
the C-terminus of the antibody (Fig. 9C). An isotype control antibody containing 
the peptides was also generated (Fig. 9D). Identical antibodies containing the HEL 
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protein (Hawiger et al., 2001), larger fragments of the OVA protein (Dudziak et al., 
2007) or gag-protein (Bozzacco et al., 2007) have shown that this antibody is a 
highly efficient means of inducing an immune response. 
Soluble OVA is taken up by both macropinocytosis as well as the mannose 
receptor (Burgdorf et al., 2007). However, since we have seen that uptake was 
essentially eliminated by mature DCs (Fig. 2) (Garrett et al., 2000) and since 
mannose receptor is significantly down-regulated upon maturation, we used 
soluble OVA as a model of an antigen that would not be recognized by endocytic 
receptors on mature DCs (Fig 9A). 
For these assays, it was important to ensure that we were not detecting the 
presence of contaminating immature DCs in our mature DCs populations. W e 
therefore sorted BMDCs that were matured overnight with LPS (or left untreated) by 
two criteria: expression of the costimulatory molecule CD86 and macropinocytosis 
(Fig. 3). To select the mature cells, DCs that had been exposed to LPS for 20 hours 
were first pulsed with a small amount of fluorescently labeled soluble OVA. These 
cells were washed, then stained with anti-CD86 and CD11 c. Only CD11C+ cells 
that had no detectable soluble OVA uptake and had fully up-regulated CD86 after 
LPS treatment, were considered mature. Immature cells had no exposure to LPS 
but were otherwise treated identically, but gated on the large population of cells 
that had taken up varied amounts of soluble OVA and were CD86 low-
intermediate. 
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A second, independent assay was also devised using the Ea/YAe system. 
The monoclonoal YAe antibody acts much like a T cell receptor in that it 
recognizes a fragment of the Ea protein only when this fragment is bound to MHCII 
(Murphy et al., 1992). This antibody can then be used to assess antigen 
presentation at the single-cell level by flow cytometry. Unlike transgenic T cells, 
which are influenced by factors such as costimulatory molecules and cytokines, the 
YAe antibody measures only MHC-peptide complexes. 
In order to test our hypothesis that DCs would be able to present receptor-
targeted antigen but not untargeted antigen, we initially used two different antigen 
formulations. W e made ICs with aggregates of his-tagged Ea and anti-his antibodies 
(Fig. 11C) or used Ea aggregates alone as an untargeted antigen that should be 
taken up primarily by macropinocytosis (Fig 11B). Unlike OVA, which is isolated 
from hen eggs, the Ea protein that we used was derived from transgenic E coli. This 
protein is therefore unglycosolated and should not be taken up by lectins. 
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Results 
Mature DCs Present Receptor Targeted but Not Soluble Antigens to T cells 
BMDCs were sorted into highly purified mature and immature populations 
by the criteria as described in Fig. 3. They were then pulsed with soluble OVA, 
OVA immune complexes or anti-DEC-205-OVA for 30 min before the cells were 
washed and cocultured with OT.II CD4+ T cells specific for MHCII/OVA 
complexes. As expected, soluble OVA was efficiently presented to T cells by 
immature DCs, but not by mature DCs, reflecting the down-regulation of 
macropinocytosis (Fig. 10 A&B). When exposed to OVA immune complexes and 
anti-DEC-205-OVA however, mature DCs were even more efficient at activating T 
cells than immature DCs (Fig. 10A&B). 
There was poor presentation of DEC-205-targeted OVA by immature DCs 
(Fig. 10B). This was likely a reflection of the low levels of DEC-205 present on 
immature DCs (Fig. 1). This was not the case for FcyR-targeted ICs since these are 
taken up efficiently by both by mature and immature DCs (Fig. 3A). 
To determine if DCs matured by other maturation stimuli also presented 
receptor-targeted antigen, we induced maturation with CpG DNA which binds 
TLR9, and poly l:C which binds TLR 3. In each case, these stimuli prevented 
presentation of untargeted OVA but did not prevent the presentation of FcyR-
targeted ICs (Fig. 10C), showing that antigen presentation by mature DCs is 
possible regardless of the TLR ligand encountered. 
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The superior presentation ability of mature DCs is surprising. While it is 
possible that they actually showed increased efficiency at MHCII peptide 
generation when compared to the initially immature DCs, there are other possible 
explanations as well. Since these mature DCs received the initial maturation 
stimulus approximately 20 hours before the immature DCs, it was likely that they 
had greater levels of surface MHCII and CD86 for much of the coculture period. To 
remove differential co-stimulation as a possible factor, we coated assay plates with 
anti-CD28 antibodies. This ensured that all T cells would receive equal 
costimulation. Still, because the T cell assay measures only the ability of DCs to 
stimulate naTve T cells, we could not be certain about the relative antigen 
processing abilities of these cell types. 
Direct Quantitation of MHCII-peptide Formation in Mature DCs 
To make this comparison, we set out to directly quantify the formation of 
MHCII-peptide complexes by immature and mature DCs. W e were able to do this 
by making use of the YAe monoclonal antibody, which recognizes a peptide 
derived from the Ea protein (52-68) when bound to MHCII (Murphy et al., 1992). 
W e compared the ability of immature and mature DCs to present aggregates 
of recombinant Ea protein, which should be taken up non-specifically (Fig. 11B) or 
Ea immune complexes, which should be taken up by FcyR (Fig 11C). For controls, 
immature and mature DCs that had not been exposed to Ea protein were used. All 
cells were treated with LPS at the time that antigen was provided. 
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Immature DCs formed MHCII-peptide complexes from untargeted Ea 
protein significantly better than the previously matured DCs, most likely reflecting 
their different capacities for macropinocytosis (Fig. 12 A&B). However, immature 
and mature DCs were able to generate specific MHCII-peptide from Ea-immune 
complexes with comparable efficiency (Fig. 12A&B). 
Since we had previously established that both immature and mature DCs 
efficiently internalize opsonized particles (Fig. 8), we used opsonized E. coli that 
express the Ea protein to compare the presentation of MHC-peptide complexes 
from this physiologically relevant source of antigen (Fig. 11 A). Otherwise identical 
bacteria that did not express the protein were used as a control. As was seen for 
presentation of ICs, both immature and mature DCs generated similar levels of 
MHCII-peptide complexes after phagocytosis of bacteria-associated antigen (Fig. 
13). Thus, although mature DCs lose the ability to present untargeted antigens, 
their ability to present antigens on MHCII molecules following receptor-mediated 
uptake by clathrin coated pits or phagocytosis remains entirely intact. 
Mature DCs Cross-present Receptor Targeted Antigens 
Previous studies have suggested that mature DCs lose the ability to cross-
present antigen on MHCI molecules, while retaining their ability to present 
endogenous antigens. This has been attributed to a lack of (non-specific) antigen 
internalization (Wilson et al., 2006), or poor translocation of antigen to the cytosol 
(Gil-Torregrosa et al., 2004). To assess cross-presentation, we returned to the OVA 
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system and targeted OVA to the FcyR and DEC-205 using OVA ICs or anti-DEC-
205-OVA, respectively. W e found that mature DCs cross-presented this antigen far 
more efficiently than immature DCs (Fig. 14). 
While the mechanism of cross-presentation on MHCI is still poorly 
understood, the increased levels of MHCI synthesis in mature DCs (Delamarre et 
al., 2003) likely explains the level of cross-presentation if antigen is efficiently 
internalized. Our studies differ from previous work by making use of receptor-
mediated rather than non-specific endocytosis (Wilson et al., 2006), or by using a 
more sensitive T cell assay that more clearly revealed the cross-presentation that 
was indeed observed earlier (Gil-Torregrosa et al., 2004). 
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Discussion 
The model of the immature DC as antigen gatherer and the mature DC as 
antigen presenter is well established for a series of reasons. First, it makes sense in 
an immunological context, in that it can be invoked as a mechanism to prevent 
autoimmunity. Second, it is suggested by DC cell biology since maturation leads to 
both down-regulation of macropinocytosis and translocation of available MHCII 
from the loading compartment to the plasma membrane. And most importantly, 
there is in vitro and in vivo data showing that mature DCs no longer efficiently 
newly encountered antigens (Romani et al., 1989; Young et al., 2007). 
Despite these past findings, relatively little work has been done to rigorously 
test this hypothesis. In agreement with previous literature, we found that DCs that 
had previously been matured with a variety of maturation stimuli did not efficiently 
present soluble OVA or Ea aggregates (Fig. 10 & Fig. 12). However, we found that 
if these antigens were targeted to DEC-205 (Fig. 10A) or the FcyR (Fig. 10B & Fig. 
12) they were taken up and presented efficiently. 
W e measured presentation both with naTve T cells capable of recognizing 
OVA fragments in the context of MHCI or MHCII (Fig. 10 and Fig. 14) and with the 
YAe antibody, specific for MHCII-Ea peptide complexes (Fig. 12 and Fig. 13). The 
OVA system is well established, highly sensitive and physiologic in that the readout 
reflects T cell activation. In contrast, the Ea system only measures MHC-peptide 
complexes. While this is a less physiologic system, it is not influenced by 
differences such as costimulatory molecule surface expression or cytokine 
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production. Together, these data conclusively demonstrate that antigen processing 
and presentation is active in mature DCs. 
These findings contradict the concept that mature DCs are specialized 
purely for antigen presentation of previously acquired antigens and play no further 
role in antigen acquisition. However, our data are not in direct conflict with any 
particular report. Past reports have looked at DCs matured by culture of 
dissociated lymphatic tissue rather than inflammatory stimulus and/or have used 
antigens that should theoretically be taken up more efficiently by immature DCs 
(Romani et al., 1989; Young et al., 2007). W e are not aware of any other studies 
that have targeted antigen to endocytic receptors to ensure adequate uptake. 
Importantly, we confirmed that antigen was delivered to the same antigen-
loading compartment in both immature and mature cells (Chapter 2). There have 
been reports of differential trafficking of antigen receptors upon maturation 
(Engering et al., 2002b) and of the route of antigen uptake influencing presentation 
(Burgdorf et al., 2007). For these reasons, it is vital to confirm that uptake and 
trafficking of antigen is equivalent in any study that attempts to compare the 
antigen processing ability of two cell types. 
The finding alters the concept of the "snapshot hypothesis," the notion that a 
DC presents a "snapshot" of the antigenic environment at the time that maturation 
is induced (Villadangos et al., 2005). Perhaps this is taking the analogy too far, but 
a DC may act more like a camcorder, presenting a selection of antigens 
encountered after TLR stimulation. However, in this case antigen presentation 
70 
correlates with receptor expression. This gives us strong motivation to better 
characterize the roles of endocytic receptors and their modulation by inflammatory 
stimuli. The immunological implications of mature DCs presenting self or foreign 
antigens long after their initial activation are discussed later in this work. 
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Materials and Methods 
Generation of BMDCs 
As described in Chapter 2 
Antibodies 
Anti-CD86-FITC/ PE/APC (GL1), anti-CD8a-PerCP (53-6.7), anti-CD45R-Pacific 
Blue (RA3-6B2), anti-CD11c-PE-Cy5 (HL3), were purchased from BD. Anti-6xHis 
was purchased from Sigma and Serotec. Polyclonal rabbit anti-£. coli-FITC was 
purchased from Serotec. Anti-MHCII/Ea peptide (52-68)-biotin (YAe) was 
purchased from eBiosciences. Anti-OVA (Delamarre et al., 2003) is a rabbit 
polyclonal antibody. Anti-DEC-205-OVA and the isotype control-OVA (gifts from 
Ralph Steinman, Rockefeller University, NYC, NY) are hybrid antibodies containing 
the amino acid residues OVA 257-264 and OVA 323-329 at the C-terminus of the 
antibodies. They were purified from stably transfected lines of mouse myeloma 
cells using the LONZA recombinant protein expression system. 
In Vitro T Cell Activation Assays 
DCs were sorted as described above, and incubated for 30 min with DEC-205-
OVA, OVA immune complexes or soluble OVA in the presence of 50 pg/ml of LPS 
(Sigma). Cells were washed and the indicated number of DCs were cocultured 
72 
5x106 CD4+ or CD8+ T cells that had been purified using negative selection 
(Miltenyi) from the spleens of OT.II or OT.I mice respectively. 24 hours later 
supernatants were collected and IL-2 concentration was measured by ELISA to 
determine the degree of T cell activation. 
Alternatively, DCs were incubated with CFSE labeled T cells for 60 h. T cells were 
stained with anti-CD4 antibody and were analyzed by flow cytometry to determine 
the extent of cell division. CD4+ T cells were gated and CFSE dilution was 
assessed. The percentage of dividing cells was determined for each sample. Anti-
DEC-205-OVA was a gift from Ralph Steinman and was prepared from stably 
transfected lines of mouse myeloma cells using the LONZA recombinant protein 
expression system. Immune complexes were made from polyclonal rabbit anti-
OVA antibodies mixed at a 3:1 molar ratio with OVA (Worthington). Soluble OVA 
(Worthington) was purified by centrifugal filtration (Millipore) or size-exclusion 
chromatography (Bio-Rad) to remove impurities and pre-formed peptides. 
Quantitation of IL-2 Production by ELISA 
Maxisorb 96 well plates (Nunc) were coated with anti-IL-2 mAb in a phosphate 
buffer, ph 9.0 overnight. Washes were performed with 0.01% tween in PBS. 
Plates were blocked in 2 % BSA for and washed before supernatants from T cell 
activation and IL-2 standards (Peprotech) were applied to the plates. Bound IL-2 
was detected with anti-IL-2-biotin antibodies (BD) followed by streptavadin-HRP 
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and addition of a TMB substrate (Pierce). Absorbance at 405 nm was determined 
using a microplate reader (Molecular Devices). 
Generation of Recombinant l-Ea Protein 
E. coli expressing 6xHis-tagged l-Ea protein was a kind gift of Ruslan Medzhitov. 
The bacteria was grown in 2 L of LB in the presence of 100 pg/ml ampicillin and 
30pg/ml kanamycin. When the OD reached 0.6, IPTG was added to a final 
concentration of 1 mM. Bacteria were grown for 6 more hours, centrifuged and 
resuspended in 200ml of 8M urea pH 8 containing protease inhibitor cocktail 
(Roche) and 20mM imidazole. After stirring at room temperature for 4 hours the 
lysate was spun and the supernatant was incubated with nickel agarose beads 
(Qiagen). The beads were washed with 8M urea (pH 6.3) and loaded into a 
chromatography column (Bio-Rad). The recombinant protein was eluted with 8M 
urea (pH 4.5). The eluate was dialyzed against PBS using a 10,000 M W C O Slide-
A-Lyzer Cassette (Pierce). Insoluble aggregates were separated from soluble protein 
by centrifugation. Ea-immune complexes were created by mixing Ea aggregates 
with anti-his antibody on ice (Sigma or Serotec) at a 1:3 molar ratio. 
Flow Cytometry 
Cells were resuspended in PBS containing 0.5% BSA, stained for 15 min on ice 
with antibodies conjugated with FITC, PE, PE-Cy7, pacific blue, PE-Cy5 or APC, 
then washed twice with buffer. The stained cells were fixed with 1% PFA, then 
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subjected to FACS (BD Canto-II, FACSCalibur, or Aria). The collected data 
analyzed with Flowjo software. 
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Soluble OVA OVA Immune Complexes 
anti-DEC-2C)5-OVA Isotype-OVA 
Figure 9 - Antigens used to assess T cell activation by immature and mature DCs. 
(A) OVA was purified from contaminants and pre-formed peptides by centrifugal 
filtration or size-exclusion chromatography 
(B) OVA immune complexes were generated by incubating OVA with rabbit-anti-OVA 
polyclonal antibodies at a 1:3 molar ratio. 
(C) Anti-DEC-205-OVA and (D) isotype control antibodies are fusion proteins 
containing amino acid residues OVA 257-264 and OVA 323-329 at the C-terminus of 
the antibodies. 
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Figure 10 - Mature DCs efficiently present receptor-targeted antigens to CD4+ 
T cells. 
(A) Immature and mature BMDCs were sorted as in Fig. 4. They were then incu-
bated with OVA/rabbit anti-OVA immune complexes or soluble OVA for 30 min 
in the presence of LPS at 37° C. DCs were washed and cultured with 10e5 CD4+ 
OT.II T cells for 24 h. T cell activation was assessed by measuring IL-2 secretion 
by ELISA. Averages of triplicates are displayed. 
(B) Experiments performed as in (A) but with anti-DEC-205-OVA and isotype 
control-OVA fusion proteins. 
(C) BMDCs were cultured for 20 h in the presence of 50 ng/ml LPS, 10 pg/ml poly 
I:C, 10 nM CpG DNA or left untreated. The cells were incubated with OVA/rabbit 
anti-OVA immune complexes or soluble OVA for 30 min. DCs were washed and 
cultured with 10e5 CD4+ OT.II T cells for 24 h. IL-2 secretion was measured by 
ELISA. Experiment performed in triplicate. Averages of triplicates are displayed. 
Error bars indicate standard deviation. 
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Figure 11 - Model antigens used to quantitiatively measure MHCII-peptide 
complex generation. 
(A) Ea synthesis was induced in transgenic E. coli using IPTG. 
(B) Aggregates of Ea were purified from the transgenic E. coli. 
(C) Immune complexes of Ea were made by incubating Ea aggregates with 
anti-6xHis monoclonal antibodies. 
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Figure 12 - Mature DCs efficiently generate MHCII-peptide complexes. 
(A) Immature or LPS-matured BMDCs were labeled with anti-CD86, then incubated 
with 30 [Jg/ml of Ea aggregates or 30 [Jg/ml Ea aggregate immune complexes for 5 h. 
Cells were then stained with YAe antibody and anti-CD11 c and analyzed by flow 
cytometry. LPS-matured cells were gated on the CD11c+ CD86 high population. 
Immature cells were gated on the CD1 lc+ CD86 low population. 
(B) MFI of YAe staining from 2 independent experiments. Bars indicate standard error. 
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Figure 13 - Mature DCs efficiently phagocytose and present bacterial 
antigens. 
Immature or LPS-matured BMDCs were labeled with anti-CD86, then 
incubated at a 1:100 ratio with opsonized E. coli that had been induced 
with IPTG to express Ea. Uninduced bacteria were used as a control. 7 
h later, cells were stained with YAe antibody and anti-CD11 c and 
analyzed by flow cytometry. LPS-matured cells were gated on the 
CD11C+ CD86 high population. Immature cells were gated on the 
CD11 c+ CD86 low population. 
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Figure 14 - Mature DCs efficiently cross-present receptor-targeted 
antigens to CD8+ T cells. 
Immature and mature BMDCs were sorted as in Fig. 4. They were then 
incubated with OVA/rabbit anti-OVA immune complexes or soluble OVA 
for 30 min in the presence of LPS at 37° C. DCs were washed and 
cultured with 10e5 CD8+ OT.I T cells for 24 h. T cell activation was 
assessed by measuring IL-2 secretion by ELISA. Averages of triplicates are 
displayed. 
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Chapter 4: Mechanism of Antigen Presentation By Mature DCs 
Introduction 
The maturation program has been described as designed to optimize antigen 
presentation while shutting down mechanisms related to acquisition and 
processing (Reis e Sousa, 2006). Our data indicates that while mature DCs are 
more selective in their antigen acquisition, they are quite efficient at antigen 
processing (Chapter 3). W e therefore set out to determine by what mechanism 
mature DCs present antigens. 
There are few known changes that occur during maturation that would be 
expected to interfere with efficient cross-presentation on MHCI. In fact, DCs are 
known to efficiently present new endogenous antigens long after the maturation 
stimulus was received (Wilson et al., 2006) so it seems that MHCI pathway is active 
in mature DCs. In addition, MHCI synthesis is up-regulated in mature DCs 
(Delamarre et al., 2003). It is therefore not entirely surprising that mature DCs 
would have the capacity to cross-present antigen on MHCI once provided with a 
receptor-dependent route of entry into endocytic compartments, andfrom there, 
translocation to the cytosol. For this reason, and because the mechanism of cross-
presentation in immature DCs in unclear, we did not attempt to determine the 
mechanism of MHCI presentation in mature DCs in this study. 
However, the mechanism of MHCII presentation is not immediately 
apparent. First, the location of antigen loading needs to be determined. While 
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immature DCs load antigen in the lysosomal compartment, the dramatic 
reorganization of MHCII to the cell surface upon maturation suggests that little if 
any MHCII remains available for loading in mature DCs (Boes et al., 2002; Chow et 
al., 2002; Kleijmeer etal., 2001; Pierre and Mellman, 1998; Pierre etal., 1997). 
W e therefore set out to document whether internal stores of antigen could be 
detected upon closer inspection, and if so, where these stores are located. 
Secondly, the role that the down-regulation of MHCII synthesis plays needs 
to be determined. This down-regulation has been observed previously (Cella et al., 
1997; Pierre et al., 1997; Villadangos et al., 2001; Young et al., 2007) and is 
known to correlate with reductions in antigen presentation (Young et al., 2007). 
Still the reduction in MHCII synthesis has never been definitively shown to cause 
the reduction in antigen presentation. W e therefore had two additional tasks. The 
first was to confirm that MHCII synthesis is down-regulated under the conditions 
that we have been using. The second was to determine the source of loaded 
MHCII in mature DCs. 
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Results 
Visualization of Internal Stores of MHCII 
The most notable difference between immature and mature DCs when 
inspected by immunofluorescence is the nearly complete transfer of MHCII from 
the lysosomal compartment to the plasma membrane (Fig. 5). Since immature DCs 
load MHCII in the lysosomal compartment (Chow and Mellman, 2005), we asked if 
there were residual internal stores of MHCII that could be visualized with a more 
sensitive method of detection. W e hypothesized that high concentrations of MHCII 
on the plasma membrane might artifactually mask a reduced amount of MHCII in 
late endosomes or lysosomes. 
W e therefore set out to markedly reduce the surface signal so any residual 
internal stores might be revealed. W e blocked surface MHCII with unlabeled 
antibody, then fixed and permeabilized DCs before detecting internal MHCII with 
labeled anti-MHCIl antibody. Indeed, under these conditions, an internal pool of 
MHCII in mature DCs could be detected that colocalized with the lysosomal 
marker H-2M (Fig. 15). 
Next we used electron microscopy to confirm that ICs internalized via the 
FcyR accumulated in MHCII-containing lysosomes over time. HRP-anti-HRP ICs 
were bound to the surface of sorted, mature DCs at 4° C, then warmed to 37° C and 
fixed at various time points after internalization began. Labeling for MHCII was 
performed. W e found that by 60 min after internalization that approximately 80% 
of the ICs were localized to MHCII positive compartments (Fig. 16A&B). This data 
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indicates that both MHCII and newly internalized antigen are together in the same 
place at the right time for peptide loading to occur. 
Monitoring of Internal MHCII-Peptide Formation 
To more definitively determine whether peptide-loading can occur in the 
MHCII-diminished lysosomal compartment of mature DCs, we once again took 
advantage of the specificity of the YAe antibody for MHCII-Ea peptide complexes. 
We incubated mature and immature DCs with Ea immune complexes, which we 
had previously shown to be internalized and presented by both cell types (Fig.12). 
After 90 min, we washed the cells and either mounted and fixed them, or 
incubated them at 37° C for another 18.5 hours before fixation. W e then used YAe 
antibody to track the formation and the distribution of the newly formed MHCII-
peptide complexes over time. 
By 90 min, both mature and immature DCs had the majority of MHCII-
peptide complexes localized to the lysosomal compartment (Fig. 17). These 
complexes were translocated to the plasma membrane with further incubation (Fig. 
17), as found previously for immature DCs that are induced to mature (Turley et al., 
2000). W e conclude that like immature DCs, mature DCs load antigenic peptides 
on MHCII in the lysosomal compartment and then make the MHCII-peptide 
complexes available on the plasma membrane for T cell recognition. 
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The Role of Newly Synthesized MHCII in Mature DCs 
While mature DCs appear to continue to form MHCII-peptide complexes in 
the lysosomal compartment, the source of the MHCII is still unclear. Previous work 
has suggested that antigenic peptides can be loaded both on newly synthesized or 
on recycling MHCII molecules (Trombetta and Mellman, 2005). However the 
down-regulation of MHCII synthesis after maturation has been proposed as the 
mechanism responsible for reduced presentation of newly acquired antigens by 
mature DCs (Young et al., 2007). W e therefore decided to document whether this 
down-regulation of MHCII was indeed occurring in our system, and if so whether it 
was complete. 
W e first examined the rate of MHCII synthesis in immature and mature DCs 
by metabolic labeling and autoradiography. As in the antigen presentation 
experiments, these cells were sorted to high purity to ensure that MHC production 
by mature DCs could be attributed to synthesis by this population rather than to 
contaminating immature DCs. Like previous studies, (Cella et al., 1997; Pierre et 
al., 1997; Villadangos et al., 2001; Young et al., 2007) we found significant but 
incomplete down-regulation of MHCII synthesis after maturation. MHCII synthesis 
was decreased by -90% in mature BMDCs and 65% in splenic DCs (Fig. 18). 
To determine the contribution of the residual de novo synthesis of MHCII to 
peptide loading, we used cycloheximide (CHX) to arrest protein synthesis. W e 
found that at doses as low as 1 pM, there was nearly complete inhibition of protein 
synthesis, yet that this was fully reversible after washout, showing that the cells 
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were not killed by this dose of CHX (Fig 19A). Immature and mature DCs were 
pulsed with CHX 30 for min before the cells were pulsed with Ea immune 
complexes. The CHX pulse prevented DCs from using newly synthesized MHCII to 
load peptides. 5 hours later, MHCII peptide surface presentation was detected with 
YAe. 
W e found that CHX treatment significantly impaired, but did not completely 
abrogate, the formation of YAe-reactive MHCII-peptide complexes in immature 
DCs, demonstrating the contribution of both newly synthesized and recycled 
MHCII to peptide loading (Fig. 19B). Interestingly, CHX had little effect in fully 
mature DCs, indicating that recycled or previously synthesized MHCII plays a 
major role in the presentation of newly captured antigens (Fig. 19B). 
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Discussion 
Here we show that the mechanism of antigen presentation by mature DCs 
has both similarities and differences to the mechanism in immature DCs. As with 
immature DCs, antigen is trafficked to the lysosomal compartment (Fig. 16). This is 
where we visualized the formation of MHCII-peptide complexes in both cell types 
(Fig. 19). However, we confirmed a significant reduction in MHCII synthesis by 
mature DCs (Fig. 18) (Cella etal., 1997; Pierre et al., 1997; Villadangos etal., 
2001; Young et al., 2007). This reduction was not complete, so there was 
theoretically still newly synthesized MHCII available for loading (Fig. 18). 
However, administration of CHX led to a much greater reduction in presentation by 
immature DCs, suggesting that newly synthesized MHCII plays a smaller role in 
presentation by mature DCs (Fig. 18). 
This could indicate that recycling MHCII plays a larger role in antigen 
presentation by mature DCs. However, recycling is problematic for several 
reasons. First, although the recycling pathway is well-established with certain 
antigens, there is evidence that most antigens are efficiently presented on newly 
synthesized rather than recycled MHCII (Geuze, 1998; Pinet et al., 1995). Testing 
the ability of mature DCs to present antigens other than OVA and Ea would be 
helpful but would still leave another issue unresolved: the marked stabilization of 
MHCII on the plasma membrane of mature DCs by a loss of ubiquitination (Shin et 
al., 2006). Maturation leads to the stabilization of MHCII on the cell surface, with 
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the MHCII half-life increasing at least 10-fold (Cella et al., 1997). This long half-life 
makes surface MHCII a less likely reservoir for newly acquired antigens. 
Still, while ubiquitin signals the sorting of MHCII molecules to late 
endosomes and lysosomes (Shin et al., 2006), it is less clear that it is necessary for 
the initial step of endocytosis. This is true not only for MHCII but also for receptors 
such as the EGF receptor for which the role of ubiquitin is quite well characterized 
(Sorkin and Goh, 2009; Stahl and Barbieri, 2002). Thus, even in mature DCs, a 
small level of MHCII endocytosis might be expected to continue. The size of the 
intracellular pool would undoubtedly remain small under steady state conditions. 
The small intracellular pool of MHCII that we observed (Fig. 15) appeared 
sufficient for effective antigen processing and presentation (Chapter 3). However it 
is minimal compared to the large intracellular pools of MHCII observed in 
immature DCs (Fig. 17, top row)(Turley et al., 2000). Is it possible that such large 
pools of MHCII are not essential for efficient antigen presentation? Studies of B 
cells and B cell lines may suggest that this is the case as they too are efficient 
antigen presenters with only small intracellular pools of MHCII (Trombetta and 
Mellman, 2005). 
Perhaps we will gain more insight into the function of mature DCs from B 
cells. Both cell types must recognize of antigen via endocytic receptors for efficient 
uptake. Both have high levels of surface MHCII while having relatively small stores 
of internal MHCII. 
89 
Materials and Methods 
Generation of BMDCs 
As described in Chapter 2 
Antibodies 
Mouse IgG, anti-HRP-Cy5, anti-HRP-biotin were purchased from Jackson 
ImmunoResearch Laboratories. Anti-CD86-FITC/ PE/APC (GL1), anti-CD8a-PerCP 
(53-6.7), anti-CD45R-Pacific Blue (RA3-6B2), anti-CD11 c-PE-Cy5 (HL3), anti-
MHCII-biotin/unlabeled (KH74), MHCII (TIB-120) and streptavidin-PE were 
purchased from BD. Anti-6xHis was purchased from Sigma and Serotec. Anti 
MHCII/Ea peptide (52-68)-biotin (YAe) was purchased from eBiosciences. Anti-H-
2M (Pierre et al., 1997), anti-MHCI (Delamarre et al., 2003) were rabbit polyclonal 
antibodies. Secondary antibodies were purchased from Molecular Probes. 
Metabolic Labeling 
BMDCs or splenic DCs (5x106) were pre-incubated in RPMI without met/cys 
(Invitrogen) for 15 min, then proteins were labeled with medium containing S35-
met/cys (Amersham) for 20 min. Cells were lysed in buffer containing 1% Triton X-
100, then subjected to immuno-precipitation of MHCII and MHCI proteins using 
TIB-120 and a rabbit polyclonal respectively. The proteins were loaded to SDS-
PAGE and imaged by phospho-image analyzer (Amarsham-Pharmacia Typhoon). 
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Confocal Microscopy 
BMDCs were seeded on alcian blue-coated coverslips at 37° C for 15 min. Cells 
were washed with PBS and fixed with 4% paraformaldehyde. Cell were blocked 
and permeabilized in a buffer containing 10% goat serum, 10mM Hepes, pH 7.4, 
10 mM glycine and 0.05% saponin. Cells were stained with a rabbit anti-H-2M 
polyclonal antibody, anti-MHCII antibody (K4H7) and YAe-biotin. Secondary 
antibodies were obtained from Molecular Probes. Imaging was performed with a 
Zeiss LSM 510 or Leica SP5 confocal microscope. 
Electron Microscopy 
Cells were labeled at 4°C with anti-HRP-biotin/HRP immune complexes for 15 
min. Cells were washed and labeled with 10 nm anti-biotin-gold (Aurion). Cells 
were fixed in suspension in 4 % PFA, 0.25M HEPES buffer, pH 7.4 for 1 hr at room 
temp. Concentration of PFA was increased to 8% in the same buffer and cells were 
stored overnight. Cells were then embedded in 10% gelatin, infiltrated in 2.3 M 
sucrose in PBS and frozen in liquid nitrogen. 70 nm cross-sections were cut on a 
Leica Ultracut cryo-microtome and collected on 100 hexagonal nickel grids coated 
with formvar and carbon. Sections were labeled with anti-MHC class II (TIB-120) 
or anti-LAMP-2 followed by rabbit anti rat antibody and 5 nm protein A gold, then 
incubated with 1.8% methyl cellulose and 0.5% uranyl acetate and air dried. They 
were examined with a Tecnai 12 Biotwin electron microscope (FEI). Images were 
recorded using a Morada CCD camera (Olympus Soft Imaging Solutions). For 
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quantitation approximately 30 images were taken at random. The percentage of 
DEC-205 gold or immune complex-gold contained within MHCII labeled structures 
were counted. 
Flow Cytometry 
Cells were resuspended in PBS containing 0.5% BSA, stained for 15 min on ice 
with antibodies conjugated with FITC, PE, PE-Cy7, pacific blue, PE-Cy5 or APC, 
then washed twice with buffer. The stained cells were fixed with 1 % PFA, then 
subjected to FACS (BD Canto-ll, FACSCalibur, or Aria). The collected data was 
analyzed with Flowjo software. 
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Figure 15 - Detection of intracellular MHCII positive compartment. 
LPS-matured BMDCs were blocked with 10 |Jg/ml of unlabeled anti-MHCIl 
(bottom) or not blocked (top) before fixation in 4% PFA. Cells were then 
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Figure 16 - Mature DCs traffic antigen to lysosomes containing MHCII. 
(A) LPS-matured BMDCs were sorted as described in Fig. 4 and labeled with HRP-
anti-HRP immune complexes-biotin for 15 min, washed, then labeled with anti-
biotin gold for 15 min. Cells were incubated at 37° C for the indicated times before 
fixation. Scale bars, 100 nm. 
(B) 30 random images were acquired of fields containing at least one immune 
complex-gold containing vesicle. These vesicles were identified as MHCII positive or 
negative compartments at 5 min, 20 min or 60 min after internalization. 
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Figure 17 - Mature DCs generate MHCII-peptide complexes in the 
lysosomal compartment. 
Immature or LPS-matured BMDCs were sorted as in Fig. 4 and incu-
bated at 37° C for 90 min with Ea ICs (30 pg/ml) and LPS. Cells were 
washed, then fixed or incubated at 37° C for an additional 18.5 h 
before fixation. Cells were stained with YAe, anti-H-2M and anti-
MHCIl antibodies, and analyzed by confocal microscopy. 
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Figure 18 - Mature DCs partially down-regulate MHCII synthesis. 
Immature or LPS-matured BMDCs or splenic DCs from LPS or PBS injected 
mice were sorted as in Fig. 4. They were then incubated for 15 min in 
cys/met free media before addition of met/cys S35 for 20 min. Cells were 
washed in cold PBS supplemented with 1% FBS and lysed in triton lysis 
buffer. MHCII and MHCI were immunoprecipitated sequentially from lysates 
and run in a 10% SDS/PAGE and visualized by autoradiography. 
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Figure 19 - Inhibition of protein synthesis significantly inhibits MHCII-
peptide generation in immature but not mature DCs. 
(A) Immature or LPS-matured BMDCs were pretreated with the indicated 
amount of CHX for 30 min. In indicated samples, CHX was washed out before 
all samples were incubated for 15 min in cys/met free media (with or without 
CHX) before addition of met/cys 35S for 20 min. Cells were washed in cold 
PBS supplemented with 1% FBS and lysed in triton lysis buffer. Lysates were 
run on a 10% SDS/PAGE and visualized with a phospho-imager. 
(B) Immature or LPS-matured BMDCs were stained with anti-CD86, then 
incubated with CHX (1 |Jg/ml) for 30 min. Ea immune complexes (30 |Jg/ml) 
were added to the DCs for 5 h before staining with YAe antibody and anti-
CD11 c. Cells were analyzed by flow cytometry. LPS-matured cells were 
gated on the CD11C+ CD86 high population. Immature cells were gated on 
the CD11C+ CD86 low population. 
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Chapter 5: In Vivo Antigen Capture and Presentation By Mature 
DCs 
Introduction 
The previous chapters have outlined how mature DCs present receptor-
targeted antigens in vitro (Chapter 3) and suggested how this can occur 
mechanistically (Chapters 2 & 4). Next we decided to determine if these findings 
are applicable to the initiation of an immune response under inflammatory 
conditions in vivo. 
There are several studies that have assessed the ability of mature DCs to 
present antigens in vivo. One study, examining the ability of pre-matured DCs to 
present antigens on MHCI, showed that while presentation of endogenous antigen 
persists, cross-presentation does not occur (Wilson et al., 2006). The authors 
attributed this to poor antigen uptake by mature DCs, as the lack of antigen 
presentation correlated with significantly decreased phagocytosis in these cells. 
Since we have seen that efficiently internalized antigens are cross-presented 
efficiently (Fig. 14), reduced antigen uptake is indeed the most likely explanation 
for poor cross-presentation in vivo under inflammatory conditions. 
This same group has also assessed presentation on MHCII in vivo. They 
found that mature DCs did not activate transgenic T cells if the mice were primed 
with inflammatory stimuli before immunization with soluble OVA. In this case, 
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they attributed the lack of presentation not to poor antigen uptake, but to reduced 
MHCII synthesis (Young et al., 2007). 
However, another possible explanation for their findings, and one that 
would be consistent with their previous study of MHCI presentation, is that the 
mature DCs did not efficiently internalize the OVA protein that was used as their 
model antigen. W e therefore set out to devise an in vivo assay where we could 
measure presentation of receptor-targeted antigens by mature DCs after induction 
of systemic inflammation with LPS. 
The Villadangos group used a common method of assessing antigen 
presentation in vivo involving the adoptive transfer of CFSE-labeled T cells 
(Gudmundsdottir et al., 1999; Wells et al., 1997; Young et al., 2007). Over the 
course of several days, activated T cells divide, each division leading to a dilution 
of the labeling dye. Such dilution can be assessed by flow cytometry at a single 
cell level, and can be accurately used to monitor the immune response to a given 
antigen. 
Their group saw reduced T cell proliferation when antigen was administered 
after 9 hours of systemic inflammation, which they attributed to the reduced MHCII 
synthesis that accompanies DC maturation (Young et al., 2007). W e decided to 
repeat this experiment with receptor-targeted antigens, yet felt however, that it 
would be difficult to interpret such an experiment using the same methodology. 
While the absence of proliferation arguably shows the lack of effective antigen 
presentation, the presence of proliferation could be due to either presentation by 
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mature DCs or presentation from a re-emerging population of immature DCs. 
While maturation is a terminal differentiation program, in vivo there are DC 
precursors that are theoretically ready to step in and play the role of a 
phenotypically immature DC. Over several days, it would be impossible to rule 
out a contribution from newly generated immature DCs. 
For this reason, we wanted to be able to assess T cell activation within hours 
of antigen presentation by mature DCs. W e therefore began our in vivo studies by 
assessing T cell activation by measuring CD69 up-regulation of adoptively 
transferred CD4+ OT.II T cells. CD69 is one of the earliest markers of T cell 
activation and is up-regulated within an hour after the T cell signaling is initiated 
(Craston et al., 1997). This way there would not be enough time for the 




Reduced Presentation of Receptor-Targeted Antigen In Vivo 
To induce systemic inflammation leading to the maturation of splenic DCs, 
we injected mice with 3 pg of LPS i.p. Control mice were injected with PBS. So 
that our results would be comparable to previous studies, we then waited 9 hours 
to allow for functional maturation before immunizing mice intravenously with 
soluble OVA or OVA immune complexes. T cell activation was assessed by 
measuring CD69 up-regulation of adoptively transferred CD4+ OT.II T cells. 
In control mice that were injected with either soluble OVA or with immune 
complexes, we observed robust splenic T cell activation (Fig. 20, top row). In 
agreement with our in vitro data, there was poor T cell activation when soluble 
OVA was administered to mice that had previously been treated with LPS (Fig. 20, 
left column). However, we also found that there was poor presentation of 
receptor-targeted immune complexes under inflammatory conditions (Fig. 20, 
second column from left). Importantly, injection of peptide, which does not 
require internalization or processing, led to robust T cell activation (Fig. 20, third 
column from left). This shows that T cell activation itself is not impaired due to the 
systemic inflammation induced by LPS. 
This data, which suggests that even receptor-targeted antigen is not 
presented efficiently by pre-matured DCs is inconsistent with our in vitro 
experiments in chapter 3. W e felt that there were two general explanations that 
were most likely. The first is that splenic DCs behave differently than the BMDCs 
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that we used for most of our in vitro assays. The second is that mature DCs do no 
acquire antigens efficiently under conditions of systemic inflammation in vivo. This 
could be due to either poor uptake at the cellular level, or through systemic 
changes that reduce the concentration of antigens in the local environment. 
Splenic DCs Efficiently Present Receptor-Targeted Antigens In Vitro 
To determine whether splenic DCs behaved differently than BMDCs, we 
tested whether splenic DCs that were matured in vivo could present antigens 
delivered in vitro. As before, we matured DCs in vivo with LPS delivered i.p. or 
injected mice with PBS to leave the cells immature. Splenic DCs were harvested 9 
hours later. W e then incubated these cells with antigen and assessed their ability 
to present antigen to naVve T cells. Here we found that mature DCs presented both 
DEC-205-OVA and OVA-immune complexes at levels consistent with what we had 
observed with BMDCs (Fig. 21). Again, T cell activation was higher in mature DCs 
than immature DCs. However, unlike what we had observed with BMDCs, we 
found that mature splenic DCs presented soluble OVA comparably with immature 
DCs (Fig. 21). Regardless, it was unlikely that the reduced presentation by mature 
DCs in vivo was due to an inherent difference between splenic DCs and BMDCs. 
W e now determined that it was most likely that under the inflammatory 
conditions that we induced in vivo, mature splenic DCs had reduced access to 
antigens. To initially test this hypothesis, we conducted an experiment in which 
both the maturation stimulus and antigen were delivered in vivo, followed by an in 
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vitro assessment of antigen presentation. This way we could rule out the possibility 
that systemic inflammation somehow interferes with DOT cell interactions in vivo. 
In these experiments, LPS or PBS controls were injected i.p. 9 hours before soluble 
OVA or OVA immune complexes were delivered i.v. DCs were harvested 9 hours 
later and cocultured with CFSE labeled T cells in vitro. As with the entirely in vivo 
assay, we witnessed poor presentation of antigen by mature DCs, regardless of the 
type of antigen used (Fig. 22). This experiment added support to our the hypothesis 
that lack of in vivo antigen presentation is most likely due to poor antigen 
acquisition. 
Reduced Antigen Acquisition in Vivo 
Our previous experiments, when taken together, strongly suggested that it 
was not an intrinsic inability of mature DCs to present antigen, but a lack of 
opportunity. W e tested this hypothesis more directly by assessing the ability of i.v.-
injected fluorescently labeled anti-DEC-205 antibodies to bind mature splenic DCs 
in situ. Binding of i.v.-injected antibody would require only that the antibody 
reach the cells: any modulation of endocytic activity should not alter the readout as 
it would with fluid phase tracers. Importantly, levels of DEC-205 in CD8a+ cells 
remain stable after maturation (Fig. 1B). 
Mice were treated with LPS i.p. or with PBS control, as they had been in 
previous in vivo experiments. Fluorescently labeled anti-DEC-205 or isotype 
control antibody was injected i.v. Two hours later, spleens were harvested, and 
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DCs were analyzed by flow cytometry. Compared to immature splenic DCs, 
mature splenic DCs in LPS-treated mice showed greatly reduced labeling with the 
antibody (Fig. 23A). This result further suggests that systemic inflammation may 
limit access of splenic DCs to antigens. 
Reduction of Splenic Blood Flow Under Inflammatory Conditions 
The conditions that we and others have used to induce DC maturation in 
vivo are highly inflammatory, and may lead to a host of systemic changes, only one 
of which is the activation of the DC maturation program. After administration of 
TLR agonists, we had observed that the spleens change in nature, becoming darker 
and more friable. We asked if an alteration in something as simple as splenic 
perfusion itself could interfere with entry of antigen or even DC precursors, and at 
least partially explain the reduced access of mature DCs to antigens in vivo. 
The development of microbubble contrast agents has allowed for the use of 
ultrasound technology detecting flow within microvessels as small as 7-10 [jm. 
This technology allows for quantification of perfusion through the measurement of 
changes in signal intensity over time in a particular region of interest (Li et al., 
2002; Schwarz et al., 1993). This technique has been used to monitor perfusion of 
tumors in murine cancer models (Fleischer et al., 2004), and we thought it could be 
a useful, non-invasive method of assessing splenic blood flow under inflammatory 
conditions. 
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Once again, we injected mice i.p. with LPS or PBS. Nine hours later, we 
administered microbubble contrast agent and assessed splenic perfusion via 
ultrasound. W e observed a significant and reproducible (though incomplete) 
reduction in blood flow in the LPS-treated mice (Fig. 23B&C). This alteration may 
explain the failure of splenic DCs to access IV-injected antigen in our, and in 
previous studies. 
Mature LN DCs Efficiently Present New Antigens 
It is unclear how relevant this reduction of splenic DC access to antigen is 
under normal conditions. The i.v. injection of LPS most likely mimics sepsis, 
which is relatively rare though frequently fatal (Hotchkiss and Karl, 2003). 
However, the vast majority of infections are local, and immune responses are 
generated from interactions arising in draining LNs. Unlike the spleen, which 
acquires antigens through blood flow, the LNs receive input from afferent 
lymphatics. Antigens either drain from the periphery or are carried in by migratory 
DCs. W e hypothesized that since blood flow was not involved in transporting 
antigens, there might be equal access of antigen to draining LNs even under 
circumstances such as systemic inflammation. 
W e therefore chose to examine the ability of LPS-matured DCs to access 
and present antigens in lymph nodes (LN). W e found that while injection of LPS 
leads to full maturation of all LN DCs (Fig. 24A), access of antigen via lymphatics 
was not altered (not shown). W e therefore chose to assess antigen presentation 
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within draining LNs in vivo using the previously established method of injecting Ea 
protein as a model antigen and assessing antigen presentation using the YAe 
antibody (Itano et al., 2003). 
W e again induced maturation with injection of LPS or PBS control i.p. Nine 
hours later, we injected Ea immune complexes or Ea aggregates s.c. in the hind 
hocks of the mice. Four hours later, we harvested the draining popliteal LNs and 
assessed antigen presentation using the YAe antibody. W e found similar levels of 
presentation by immature DCs of the two antigen formulations on MHCII. 
However, consistent with our in vitro data, only Ea immune complexes were 
efficiently presented by LPS-matured LN DCs (Fig. 24B). These data indicate that 




The relevance of features of the DC maturation program to the immune 
response in vivo has frequently been inferred from in vitro studies. Confirmation 
often proves difficult: taking the same reductionist approach in vivo is virtually 
impossible. While confirmation of the relevance of in vitro findings to physiologic 
systems is necessary, much care must be taken when interpreting results. 
Two studies have recently correlated reduced phagocytosis and levels of 
MHCII synthesis in mature DCs with impaired immune responses to pathogens or 
model antigens (Wilson et al., 2006; Young et al., 2007). W e found that in 
agreement with the latter report, splenic DCs do not present antigen introduced 
into the blood stream in vivo after the induction of systemic inflammation (Young et 
al., 2007). However, further investigation revealed that lack of presentation by 
splenic DCs is likely due to a reduction of access to antigens rather than an 
intrinsic failure of DCs (Fig. 23). Mature splenic DCs do present antigens efficiently 
if antigen is supplied in vitro (Fig. 21). Furthermore, antigen presentation occurs in 
vivo when cells have access to antigens, as is the case with LN DCs that acquire 
antigens after s.c. injection (Fig. 24B). 
The major difference that we observed between BMDCs and splenic DCs in 
vitro was that presentation of untargeted OVA was not down-regulated by mature 
splenic DCs (Fig. 21). This persistence of fluid endocytosis may reflect the fact that 
splenic DCs that have been activated in vivo were harvested relatively soon after 
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LPS administration (at approximately 9 hours). In addition, splenic DCs down-
regulate macropinocytosis with slower kinetics than BMDCs and exhibit residual 
fluid phase uptake for at least 24 hours (Garrett et al., 2000; West et al., 2004). 
Our data supporting reduced antigen access of splenic DCs under 
inflammatory conditions further underscores the difficulty of attributing changes in 
complex systems to individual modifications. It is possible to add 50 ng of LPS to 
media within a tissue culture plate, and visualize the corresponding decline in 
endocytic rate that follows hours later. It is far different to inject a mouse with the 
same compound. The resulting systemic inflammation can lead to changes in body 
temperature, blood pressure, heart rate as well as the activation of many other cell 
types, that by their very nature are designed to interact and modulate one another 
(Cinel and Opal, 2009). 
While to our knowledge, we are the first to report a reduction in splenic 
blood flow after injection of TLR ligands (Fig. 23 B&C), there are reports of 
inflammatory stimuli altering splenic organization and perfusion. It has been 
shown previously that blood flow to the spleen (Rogausch et al., 2003) and lymph 
nodes (Ottaway and Parrott, 1979; Soderberg et al., 2005) increases after the 
administration of an agent such LPS. This has been hypothesized to increase 
likelihood that a lymphocyte will find its match (Soderberg et al., 2005). Our study 
differed from the previous study of splenic perfusion in that we used 15-fold more 
LPS. While our dose of LPS is well within the range used in previous studies of DC 
maturation (Wilson et al., 2004) we witnessed dramatically different changes in 
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perfusion. The effect of LPS is dose-dependent and it is possible that the increased 
dose that we (and others) have used to assess DC maturation leads to systemic 
dysfunction. 
Still, the reduction of blood flow was incomplete and therefore unlikely to 
account for the entire reduction in T cell activation. There are other physiologic 
changes that could also lead to reduced antigen access. One that is especially 
likely is DC redistribution within the spleen. Even though resident DCs continue to 
reside in the spleen after maturation, systemic LPS administration leads to a 
migration of CD11C+ DCs from the marginal zone of the spleen to the T cell area 
(De Smedt et al., 1996; Idoyaga et al., 2009). Additionally, injections of particulate 
antigen have been shown to accumulate in the marginal zone but not the T cell 
zone of the spleen (Drutman and Trombetta, in press). This adds support to our 
hypothesis that mature splenic DCs are exposed to reduced local antigen 
concentrations that explain reduced antigen presentation. 
One piece of data contradicts this model. While splenic DCs apparently 
did not have access to i.v.-injected OVA, OVA ICs or anti-DEC-205 antibody, they 
did have access to i.v.-injected OVA peptides, which were presented with high 
efficiency, even under inflammatory conditions (Fig. 20). Although we do not have 
a definitive explanation for this finding, it is possible that small peptides have 
greater access to mature splenic DCs than larger, intact proteins. Moreover, 
peptides were delivered in amounts that led to dramatic CD69 elevation (Fig. 20). 
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It is possible that reduced levels of peptide on the mature splenic DCs were not 
detected due to saturation of the system. 
Still, we do not wish to overstate the importance of reduced antigen access 
by mature splenic DCs. Its implications for understanding how to interpret past in 
vivo models of DC maturation are probably greater than any implications for 
understanding how the generation of immune responses proceed under physiologic 
conditions. Induction of systemic inflammation through introduction of 
micrograms of purified LPS or other TLR ligand into the bloodstream of an 
organism may mimic sepsis, but is unlikely to truly model how mature DCs 
function in the majority of circumstances. Since LN DCs are able to present 
antigens even under these conditions, we know that presentation of receptor-
targeted antigen can occur in vivo, just as it does in vitro. Still, the frequency with 
which this happens, and the immunological implications, remain to be determined. 
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Materials and Methods 
In Vivo Splenic DC Antigen Presentation Assays 
1 x106 CFSE labeled T cells were injected into the tail veins of mice. 24 h later 
mice were injected i.p. with 3 pg LPS or PBS control. After an additional 5 h, 
OVA-immune complexes or soluble OVA were injected i.v. Spleens were 
harvested and T cell activation was assessed by CD69 up-regulation of CFSE 
positive cells, 4 h after antigen injection. Alternatively, soluble OVA or DEC-205 
OVA was injected subcutaneously into the hind leg hocks of OT.II mice 9 h after 
i.p. injection with 3 pg LPS or PBS. Popliteal LNs were harvested 4 h later and 
assessed by CD69 up-regulation of CD4+ T cells. 
Ex Vivo Antigen Presentation Assay 
DCs were incubated for 30 min with DEC-205-OVA, OVA immune complexes or 
soluble OVA in the presence of 50 pg/ml of LPS (Sigma). Cells were washed and 
the indicated number of DCs were cocultured 5x106 CD4 or CD8 T cells that had 
been purified (Miltenyi) from the spleens of OT.II or OT.I mice respectively. 60 
hours later CFSE labeled T cells were stained with anti-CD4 analyzed by flow 
cytometry to determine the extent of cell division. Immune complexes were made 
from polyclonal rabbit anti-OVA antibodies mixed at a 3:1 molar ratio with OVA 
(Worth ington). 
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In Vivo LN DC Antigen Presentation Assay 
25 [jg of Ea aggregates or Ea immune complexes were injected into the hind leg 
hocks 9 hours after i.p. injection with 3 pg LPS or PBS control. Popliteal LNs were 
harvested 4 h later. 4 LNs from each condition were pooled so that there would be 
a sufficient number of cells for analysis. LNs were incubated in cell dissociation 
buffer (invitrogen) containing liberase blendzyme II and DNAse at 37° C for 20 
min. Cells were labeled with YAe-biotin, washed, then labeled for a second time 
with anti-CD11 c-APC, anti-CD3-Pacific Blue, anti-B220-Pacific blue. CD11c+ 
DCs were gated using Flowjo software and YAe intensity was presented as 
histograms 
In Vitro Splenic DC Antigen Presentation Assay 
Splenic DCs were obtained from the spleens of mice that had been injected IP with 
3 [jg of LPS (mature) or with PBS (immature). Tissue was cut into small pieces and 
incubated at 37° C with Liberase Blendzyme II and DNase (Invitrogen) before cells 
were dissociated by passage through a 70 |jm cell strainer (BD). Cells were 
purified with CD11c+ cell isolation beads after harvest (Miltenyi). 
DCs were incubated for 30 min with DEC-205-OVA, OVA immune complexes or 
soluble OVA in the presence of 50 [Jg/ml of LPS (Sigma). Cells were washed and 
the indicated number of DCs were cocultured 5x106 CFSE-labeled CD4+ cells that 
had been purified using negative selection (Miltenyi) from the spleens of OT.II. 
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60 h later, T cells were stained with anti-CD4 antibody and were analyzed by flow 
cytometry to determine the extent of cell division. CD4+ T cells were gated and 
CFSE dilution was assessed. The percentage of dividing cells was determined for 
each sample. Anti-DEC-205-OVA was a gift from Ralph Steinman and was 
prepared from stably transfected lines of mouse myeloma cells using the LONZA 
recombinant protein expression system. Immune complexes were made from 
polyclonal rabbit anti-OVA antibodies mixed at a 3:1 molar ratio with OVA 
(Worthington). Soluble OVA (Worthington) was purified by centrifugal filtration 
(Millipore) or size-exclusion chromatography (Bio-Rad) to remove impurities and 
pre-formed peptides. 
Flow Cytometry 
Cells were resuspended in PBS containing 0.5% BSA, stained for 15 min on ice 
with antibodies conjugated with FITC, PE, PE-Cy7, pacific blue, PE-Cy5 or APC, 
then washed twice with buffer. The stained cells were fixed with 1 % PFA, then 
subjected to FACS (BD Canto-II, FACSCalibur, or Aria). The collected data was 
analyzed with Flowjo software. 
Antibodies 
Anti-CD86-FITC/ PE/APC (GL1), anti-CD8a-PerCP (53-6.7), anti-CD45R-Pacific 
Blue (RA3-6B2), anti-CD11 c-PE-Cy5 (HL3), anti-CD69-PE (HI .2F3), and 
streptavidin-PE were purchased from BD. Anti-CD3-Pacific Blue (17A2) and anti-
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CD11 c-Pacific Blue (N418) were purchased from BioLegend. Anti-6xHis was 
purchased from Sigma and Serotec. Anti-MHCII/Ea peptide (52-68)-biotin (YAe) 
was purchased from eBiosciences. Anti-OVA (Delamarre et al., 2003) is a rabbit 
polyclonal antibody. 
Micro-ultrasound perfusion imaging 
Mice anesthetized using 2% isoflurane delivered in medical air at 1 L/sec flow rate 
were placed supine on a dedicated small animal holding system (VisualSonics Inc., 
Toronto, ON, Canada). Body temperature and heart rate were monitored for the 
remainder of the procedure (THM 150, Indus Instruments, Houston, TX, USA). 
Temperature was maintained at 37° C with a heated imaging platform. Imaging was 
performed with a Vevo 770 micro-imaging system (VisualSonics Inc., Toronto, 
Ontario, Canada) employing a single-element ultrasound transducer with a 40 
MHz center frequency and a focal length of 6 mm. A micro-bubble ultrasound 
contrast agent (Definity®, Bristol-Meyers Squibb Medical Imaging, Inc., Billerica, 
MA, USA) was administered as an intravenous bolus injection of 10 jxl through a 
jugular vein puncture. Single-slice B mode imaging was performed (center 
frequency = 40 MHz, 50% power, axial resolution = 40 (Jm, lateral resolution = 
100 |jm, 20 frames per second). The ultrasound probe was aligned perpendicular to 
the animal and the same anatomical spleen slice was determined for each animal. 
800 frames of ultrasound data were acquired for first-pass kinetics analysis, the first 
20 of which were acquired prior to contrast agent injection. First-pass kinetics 
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analysis of the signal intensity-time curve was employed to measure relative blood 
volume (BV) and vascular transit time (VTT) for each pixel (1, 2). Relative blood 





















Figure 20 - Systemic inflammation leads to decreased activation of T cells in vivo. 
10e6 CFSE-labeled OT.II CD4+T cells were injected i.v. 24 h later mice were injected 
i.p. with 3 pg LPS or PBS control. After 5 additional h, OVA immune complexes or 
soluble OVA were injected i.v. 4 h later, spleens were harvested and T cell activation 
was assessed by CD69 upregulation. 
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Figure 21 - Mature splenic DCs present antigen in vitro. 
Splenic DCs were isolated from mice injected with 3 [jg LPS or PBS i.p. DCs 
were then incubated with anti-DEC-205-C)VA, OVA immune complexes or 
soluble OVA at the indicated doses for 2 h before the cells were washed and 
co-cultured with CFSE-labeled CD4+ OT.II T cells. 60 h later the extent of cell 
division was determined by flow cytometry. Experiment performed in duplicate. 
Average values are displayed. 
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Figure 22- Reduced presentation of antigen by mature splenic DCs ex vivo. 
Mice were injected i.p. with 3 pg LPS or PBS control. 9 h later, OVA-ICs, soluble 
OVA, rabbit anti-OVA antibody as control were injected i.v. Spleens were 
harvested 2 h later and DCs were isolated and cultured with CFSE-labeled CD4+ 
OT.II T cells. 60 h later the extent of cell division was determined by flow cytom-
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Figure 23 - Systemic administration of LPS reduces access of splenic DCs to 
antigen. 
(A) 3 pg anti-DEC-205-FITC or isotype control antibody was injected i.v. into mice 
that had been pretreated for 9 h with 3 pg LPS i.p. or PBS control. 2 h later the 
spleens were harvested and DCs were analyzed by flow cytometry. Histograms of 
CD11C+ cells are displayed. 
(B) Mice were injected i.p. with 3 pg LPS or PBS control. 9 h later mice were 
anesthetized and administered 50 |jl of microbubbles via the jugular vein. Splenic 
perfusion was monitored by ultrasound. Results from 10 mice from each group 
are displayed. 
(C) Representative ultrasound images obtained during procedure outlined in (B). 
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Figure 24 - Mature LN DCs present receptor targeted antigen in vivo. 
(A) Splenic or LN DCs were harvested from LPS treated (3 pg i.p.) or PBS treated 
control mice 9 h after injection. Cells were dissociated, labeled with anti-DEC-
205, anti-CD8a, anti-CD11c and anti-CD86 and analyzed by flow cytometry. 
Plots are gated on the CD11c+ population. 
(B) Mice were injected with 3 pg LPS i.p. or PBS control. 9 h later, Ea aggregates, 
Ea aggregate ICs or PBS as control were injected subcutaneously into the hind leg 
hocks of the mice (each injection contained 1 pg LPS). 4 h later, the draining 
popliteal lymph nodes were harvested. Histograms are of CD11 c+ cells. 
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Chapter 6: Conclusions and Future Directions 
Mature DCs continue to have the ability to take up and present antigens, 
both in vitro and in vivo. This statement should be viewed as a refinement, rather 
than an upheaval of the dogma concerning DC maturation. Our finding that 
endocytic receptors remain completely functional even as macropinocytosis is 
markedly down-regulated demonstrates that DCs are not developmentally restricted 
to acquiring antigens during their immature state. Like many new findings, it will 
likely be some time before the implications are clear. 
Maturation Leads to Increased Antigen Selectivity 
W e propose a model in which part of the DC maturation program is to 
become more selective of antigen uptake. It is well established that during 
maturation, non-specific forms of endocytosis, macropinocytosis and non-receptor-
mediated phagocytosis are down-regulated (Garrett et al., 2000; Reis e Sousa et al., 
1993; Sallusto et al., 1995). Since receptor-mediated uptake remains intact (Fig. 
10, 12, 14 & 24), uptake is targeted to antigens that have already been recognized 
by the immune system (and are complexed with specific IgG) or that bind to 
specific pathogen receptors (eg lectins) on the DC surface. Self-antigens may not 
have comparable receptors and therefore would be less likely to gain entry under 
these conditions. Thus our findings need not immediately discount any role that 
modulation of antigen uptake plays in preventing presentation of self-antigens. 
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A better understanding of the various ways in which antigen is encountered 
and internalized in a physiologic setting will allow us to determine the importance 
of antigen acquisition by already mature DCs. When a larger number of DC 
antigen receptors and known ligands are compiled, it will be possible to determine 
whether receptor modulation upon maturation corresponds with the nature of the 
ligand. For instance, one might expect that DCs matured by PAMPs would down-
regulate receptors that take up primarily self-antigens while up-regulating receptors 
that target foreign antigens. Differential receptor expression by spontaneously 
matured or tolerogenic DCs has not been documented but might be expected if this 
model were accurate. 
However, as our understanding of the immune system becomes increasingly 
nuanced, the notion that the down-regulation of macropinocytosis or specific 
endocytic receptors is essential to maintaining tolerance seems less likely. When 
an immature DC encounters a pathogenic stimulus, the DC has undoubtedly 
already internalized substantial quantities of self-antigen. And while the signal 
induced by PAMP recognition indicates the presence of a pathogenic threat (Pasare 
and Medzhitov, 2005), it certainly does not indicate the absence of self-antigen. 
Indeed, phagocytosis of a bacterium does not preclude uptake of self in another 
phagosome. 
Several mechanisms are known that ensure that the immune response is 
properly focused on pathogens. Phagosome maturation has been shown to 
progress autonomously in a TLR-dependent manner (Blander and Medzhitov, 
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2004). This leads to PAMP-associated cargo being presented more efficiently than 
non-PAMP associated cargo within the same cell (Blander and Medzhitov, 2006b). 
Thus, subcellular mechanisms exist to ensure that antigen presentation is biased 
towards foreign threats, even when such cargo is internalized concurrently with 
self-antigen. If mature DCs were to continue to indiscriminately internalize both 
PAMP- and non-PAMP-associated cargo via endocytic receptors, these cells could 
presumably avoid presentation of self. 
However, there are circumstances where neither downmodulation of 
antigen uptake nor phagosome-autonomous antigen processing can explain the 
lack of presentation of self-antigens by immunogenic DCs. One especially 
problematic example would be virally infected apoptotic cells: they contain a mix 
of foreign and self (Blander and Medzhitov, 2006a). It is under these circumstances 
that it is likely that one of the many safety nets is employed. Central tolerance 
plays a vital role in preventing autoimmunity by leading to the deletion of 
autoreactive T cells before they can be released into the periphery for DC 
activation (Mathis and Benoist, 2007). Even when such autoreactive T cells escape, 
mechanisms of peripheral tolerance, such as those mediated by regulatory T cells 
can prevent pathology (Yamazaki et al., 2008). 
Implications for Timing of Antigen Acquisition 
Our findings challenge the long-standing views that DCs can only present 
antigens encountered at the time of capture and initial induction of maturation 
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(Mellman and Steinman, 2001; Villadangos et al., 2005). Since mature DCs appear 
capable of specific antigen uptake, processing, and presentation, the DC system 
would remain available to initiate T cell responses against new or mutating 
microbes and viruses during the course of an infection when many DCs are already 
mature. 
This forces us to ask the additional question of whether mature DCs can be 
"reprogrammed" to induce a qualitatively different type of immune response than 
that induced by the initial maturation stimulus, e.g. by altering the profile of 
secreted cytokines. W e think that this is likely to be the case because 
spontaneously-matured tolerogenic DCs can be induced to produce inflammatory 
cytokines by supplying a later TLR stimulus (Jiang et al., 2007). If such 
reprogramming can occur, the cytokines released during antigen presentation 
would be related to their more recent stimulus, not their original stimulus. This 
might be detrimental if two concurrent infections required different responses. 
Further research will be required to determine how DCs provide the proper 
instructions to T cells in such situations. 
Implications for Different Modes of Maturation 
Our study focused exclusively on maturation induced by TLR ligands, 
primarily LPS. While this is a highly physiologic means of DC maturation, it will 
be important to examine other forms. In the earliest studies of DCs, maturation was 
inadvertently induced by dissociation from lymphatic tissue, a necessary step in 
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obtaining populations of cells for study (Reis e Sousa et al., 1993; Steinman and 
Cohn, 1973; Steinman and Witmer, 1978). Many assumptions that we make about 
mature DCs are still inferred from studies of these cells. Now we know that 
maturation can be induced by a host of microbial products, lymphocytes via CD40 
and lymphotoxin ap receptors, cytokines, endogenous mediators such as uric acid 
and heat-shock proteins, immune complexes, and disruption of cell-cell contacts 
(Jiang et al., 2007; Steinman and Banchereau, 2007). 
The way in which maturation is induced influences the type of immune 
response generated. Unlike BMDCs matured by TLR ligands, spontaneously 
matured BMDCs have an anti-inflammatory gene expression profile and have been 
determined to induce tolerance in the EAE model (Jiang et al., 2007). On the other 
hand, like TLR-induced maturation, CD40-initiated signaling is sufficient for the 
induction of effective immune responses (Hawiger et al., 2001). However, one 
study showed that while CD40-matured DCs presented phagocytosed antigens, 
LPS-matured DCs did not (Nayak et al., 2006). Clearly, differences in antigen 
presentation and cytokine production by differentially matured DCs need to be 
understood in greater detail. 
As mentioned earlier, DCs can be activated, in vivo, indirectly by 
inflammatory cytokines such as IFNa, IFN|3, TNFa and IL-2. PAMP recognition by 
both immune and non-immune cells can lead to cytokine production to which DCs 
respond by up-regulation of both MHC molecules and costimulatory molecules. 
Interestingly, these DCs lack the ability to drive differentiation of naive CD4+ T 
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cells into effector T cells in vivo (Sporri and Reis e Sousa, 2005). It makes sense 
that these DCs should not lead to T cell activation: such indirect activation would 
be counter-productive if DCs were not presenting pathogen-derived antigens. 
However, it would clearly be harmful if indirect activation put the host's entire 
network of DCs effectively out of commission before they had the opportunity to 
access antigens. It would therefore be especially useful if DCs matured indirectly 
were able to continue to present antigens, especially if they could be 
"reprogrammed" by subsequent contact with PAMP associated antigens. 
In Vivo Significance 
Experimental models of DC maturation have involved the injection of TLR 
agonists. This induces other physiological changes that influence the ability of DCs 
to encounter antigens. It is essential to remember even as we dissect how cells 
function on an individual level that they are components of a complex larger 
system. 
W e will not be able to determine the in vivo significance of our findings 
without dissecting how these findings apply to the various DC subsets. W e expect 
that our study is likely to be broadly applicable because we have demonstrated that 
mature DCs can present antigen whether the source of the DCs was spleen, LN or 
bone marrow culture. However, we have not examined any of the migratory DC 
subsets. One might expect that these DCs would be more resistant to taking up 
and presenting new antigens since their role seems uniquely suited to presenting 
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antigens from their destination. Interestingly, this does not seem to be the case. 
One DC subset that was previously reported to present new antigens in vivo (but 
not in vitro) is the prototypically migratory Langerhans cell (Ruedl et al., 2001). 
Despite the advances made in the cell biology of antigen presentation, we 
still have a fairly limited understanding of how antigen is taken up in vivo. Most 
studies that have tested the ability of mature and immature DCs to capture and 
present antigen have been done with soluble antigens that are taken up by 
macropinocytosis. The fact that in vitro studies have for so long focused on this 
form of uptake likely overstates its importance. Presentation of antigens taken up 
via this route is extremely inefficient compared to presentation of immune 
complexes or anti-DEC-205-OVA. Previous work has demonstrated that antigens 
targeted to these receptors are presented on MHCI and MHCII over 100 fold more 
efficiently than antigens taken up non-specifically (Bonifaz et al., 2004; Regnault et 
al., 1999). These antigen concentrations are far more likely to be physiologic than 
the milligrams per milliliter of soluble antigen necessary for macropinocytosis-
mediated antigen presentation. 
Unfortunately, it is extremely difficult to examine antigen uptake and 
presentation in situ. Attempts to assess this are invariably complicated by the 
application of agents that induce systemic inflammation. However, the use of 
intravital microscopy has allowed visualization of the intricacies of T cell priming 
(Mempel et al., 2004) and even antigen sampling (Chieppa et al., 2006) by DCs 
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under physiologic conditions. Such technology could also be applied to assess 
uptake and presentation of antigen by both immature and mature DCs in vivo. 
Clinical Significance 
The simplified view of DCs as either mediators of immunity or tolerance 
glosses over the varied types of immune responses that have been demonstrated 
(Steinman and Banchereau, 2007). The roles that functionally different DCs play in 
myriad clinical situations are even more wide-ranging. DCs have been implicated 
in playing roles in infection, cancer, allergy, autoimmunity, chronic inflammation, 
transplantation and vaccination (Steinman and Banchereau, 2007). As DC 
maturation is responsible for both optimizing antigen presentation and determining 
the nature of the immune response, an enhanced understanding of DC maturation 
will no doubt play a role in how we approach DCs in our quest to maintain health 
and prevent disease. 
Presumably, the benefit of antigen uptake and processing that continues 
hours after maturation outweighs any potential harm. However, the immune 
system must constantly perform a balancing act between immunity and tolerance. 
Going too far in either direction results in disease (Cools et al., 2007). Like any 
important process, antigen presentation has the potential for dysregulation and it is 
certainly possible that in some cases disease is mediated by mature DCs presenting 
antigen inappropriately. 
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In our study we show that the FcyR mediates presentation of immune 
complexes in already mature DCs. The basic function of immune complex 
clearance is thought to be a vital part of immune homeostasis, with dysregulation 
leading to autoimmune disease such as systemic lupus erythematosus (SLE) (Takai, 
2005). It is conceivable that capture of self antigen-antibody complexes by mature 
DCs during an infection could be involved in the initiation or exacerbation of 
autoimmune disorders associated with autoantibodies such as SLE. The presence 
of FcRs on DCs have also been shown to be critical to development of 
inflammation associated with hyperresponsiveness to certain antigens (Kitamura et 
al., 2007). 
A role for mature DCs presenting malignancy-related antigens is certainly 
possible as well. While the importance of immunosurveillance in preventing and 
controlling the development of malignancies is not entirely settled, there a plethora 
of evidence of anti-cancer immune responses (Dunn et al., 2004). T-cell infiltrates 
have been detected within a variety of primary tumors and this has been associated 
with dramatically improved prognosis (Galon et al., 2006; Zhang et al., 2003). 
Tumor-infiltrating DCs have been reported as well and interestingly, the maturation 
state of these DCs has also proven important to prognosis. Patients with 
intratumoral DCs that have a mature phenotype have better outcomes than patients 
with tumors containing DCs that appear immature DCs (Chaput et al., 2008). This 
may be attributed to basic tenets of DC biology: immature DCs are likely not 
presenting tumor antigens efficiently. Still we now know that it would be possible 
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for mature DCs to promote an anti-tumor response by continuing to acquire 
antigen even while in a mature state. 
Conclusion 
Our understanding of DC biology is growing increasingly complex. While 
we once thought of a prototypical DC, we now know of multiple subsets. W e now 
know of increasingly numerous stimuli capable of inducing DC maturation and 
increasingly nuanced immune responses. In the preceding pages, we presented an 
additional layer of complexity to the DC system. The future will undoubtedly bring 
us a better understanding of how these layers of complexity interact. This should 
allow us to harness the power of the immune system to defeat infectious disease 
and malignancy or assuage the symptoms of allergy and inflammatory disease. 
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